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ABSTRACT 
Background : Virological monitoring is critical in the management of HIV-infected patients, 
providing  a standard in the assessment of disease prognosis and progression, guiding the 
initiation of ART and treatment selection, monitoring therapeutic success and establishing  
treatment failure and drug resistance. The absence of viral load monitoring can impact upon 
individual and public health through failure to maintain viral suppression, and increased risk 
of drug resistance. HIV management at the KATH HIV clinic, Kumasi, Ghana, does not 
include virological monitoring due to the lack of laboratory infrastructure and technical skills, 
thus the virological response to ART among treated patients at the centre is not fully 
understood. Moreover, data on the prevalence of HCV infection in both the general 
population and HIV-positive patients in Ghana are limited, with seroprevalence estimates 
ranging from 0.5% to 18.7% documented among different Ghanaian populations, possibly 
due to differences in study populations and the serological assays employed. Furthermore, 
these previous studies did not attempt confirmation of HCV status by PCR or RIBA. The aim 
of this study is to determine the HIV virological response in a HIV/HBV co-infected cohort 
from KATH, ascertain the specificity and sensitivity of commercially available HCV 
serological assays, and develop an assay that could be used as an alternative for HCV RNA 
testing in Kumasi.  
Methods: 247 HIV/HBV co-infected patients attending the KATH HIV clinic were recruited 
into a prospective HIV and viral hepatitis study, of which HIV-1 viral load was determined 
for 183 ART-experienced patients at study entry using the Abbott Real Time HIV-1 assay. 
The HIV-1 viral load detection among patients who had been on ART for at least 24 weeks 
was assessed. HIV positive samples from KATH with known HCV-RNA status were tested 
with two automated anti-HCV antibody assays, the Abbott Architect anti-HCV, Vitros Anti-
HCV, and two manual EIAs, Monolisa HCV Ag-Ab ULTRA, and the ORTHO HCV 3.0 
ELISA System with Enhanced SAVe. Of the last three assays the performance and the 
respective assay cut-offs likely to be indicative of RNA positivity were evaluated using their 
PCR and Architect results as reference. The development of an in-house indirect sandwich 
HCV core antigen EIA which could be used as an alternative for HCV-RNA testing was 
attempted. 
Results: Overall, 58/183 (37.4%) patients who received treatment for at least 24 weeks 
showed a viral load >40 copies/mL with a median level of 826 copies/mL (IQR: 65 - 26752). 
Their CD4 T-cell counts were lower compared to patients with undetectable viral load (P= 
0.002, Mann Whitney U test). Among the four HCV antibody assays the Ortho was found to 
be the most specific assay that could be employed in a limited resource setting such as 
Kumasi, and an S/CO ratio of 3.65 was found to be most likely to be indicative of HCV RNA 
positivity. The HCV core EIA development was not completed in time due to poor activity of 
commercially available agents. 
Conclusion: Through this study, skills in HIV viral load and EIA development have been 
acquired that could be applied to improve virological monitoring at KATH with the necessary 
infrastructure in place. Further studies are required to identify factors that are associated with 
poor viral response in this cohort. The ORTHO HCV 3.0 ELISA System with Enhanced 
SAVe can be regarded as a suitable diagnostic tool for HCV infection in Kumasi, but further 
studies are required to establish the S/CO ratio most likely to be indicative of HCV RNA 
positivity. 
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CHAPTER ONE - INTRODUCTION 
1.1  THE GLOBAL HIV EPIDEMIC 
HIV infection continues to be one of the most severe global health challenges. Currently, 34 
million (between 31 and 36 million) people are estimated to be living with the virus 
worldwide and a prevalence of about 0.8% occurs among the most productive age group, 15-
49 years. The epidemic however demonstrates significant geographic variation. Sub-Saharan 
Africa (SSA) remains the most seriously affected region with an adult prevalence of 4.9%, 
accounting for 69% of the total number of people living with HIV worldwide. This reflects 
limited access to prevention, care and treatment in this region (WHO/UNAIDS/UNICEF, 
2011). Adult prevalence rates are about 0.1% in East Asia, 0.2% in Western/Central Europe 
and 0.3% in South-East Asia and Oceania. Latin America, North America, Eastern Europe 
and the Caribbean also have ≤ 1% prevalence. Women represent about 50% of worldwide 
population living with HIV and close to 60% in SSA (UNAIDS, 2012). 
Although there has been a steady rise in the global prevalence rate from 1999 to 2011 due to 
continuing new infections, increased life expectancy of infected people, there has also been 
an overall decline by more than 20% in the number of new infections since 2001. The 
sharpest declines have occurred in the Caribbean (42%), and SSA (25%). Moreover the rate 
of AIDS-related death has reduced by 24% since 2005 (UNAIDS, 2012), reflecting anti-
retroviral scale up in many parts of the world. Globally, most new infections are as a result of 
heterosexual transmission, and this especially the case in SSA. In other regions, homosexual 
intercourse, intravenous drug use, and commercial sex work remain significant risk factors 
for infection.  
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1.2 THE HIV LIFE CYCLE 
Figure 1.1 The HIV particle 
HIV has an icosahedral structure with 
diameter ranging between 110-143nm 
(Zhu et al, 2003) (Fig 1.1). It is 
surrounded by a lipoprotein-rich bilayer 
which contains 72 external spikes 
formed by trimers of the external 
surface glycoprotein gp120 and the 
transmembrane glycoprotein gp41 non-
covalently bound together (Fanales-
Belasio et al, 2010).  The lipid bilayer is 
also studded with various host proteins 
including major histocompatibility complex (MHC) class I and II antigens and actins 
acquired during virion budding (Green et al, 1991).  
The HIV genome is approximately 9.8kb and is composed of two molecules of single-
stranded RNA enclosed by a cone-shaped capsid mainly containing p24 viral protein. 
External to the  capsid the  p17 protein forms the matrix associated with  the inner suface of 
the lipid bilayer.  The capsid also contains the viral protease (PR), reverse trascriptase (RT), 
integrase (IN), viral protein U (Vpu), viral infectivity factor (Vif), negative effector (Nef) and 
some cellular factors (Sierra et al, 2005). CD4+ T-lymphocytes, monocytes and macrophages 
are the major cellular targets for HIV infection (Letvin, 1990). HIV enters these cells by 
binding to the CD4 receptor on the cell membrane (Ratner, 1993; Klatzman et al, 1984). 
Entry also requires binding to one of several co-receptors; the chemokine receptors CCR5 
and CXCR4 are the main co-receptors for HIV-1 in vivo (Clapham, 2002). Preferential use of 
these two chemokine receptors identifies HIV tropism; strains that preferentially use CXCR4 
are designated X4; strains that use CCR5 are called R5; and strains that use both co-receptors 
are designated as dually tropic (Freed, 2001). 
Infection of target cells begins with virus entry, which requires the fusion of the viral 
envelope with the cellular membrane (Fig. 1.2). Initially, gp120 binds to the CD4 receptor 
(Nielsen et al, 2005), which causes a conformational change exposing a specific domain in 
the V3 loop that binds to the chemokine co-receptor. 
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   1        2            3         4              5  
Figure 1.2 HIV entry into the host cell. 1) gp120 binds with CD4 and the chemokine co-
receptor, 2) the gp41 fusion peptide springs out towards the host cell membrane, bridging the 
divide between the viron and the host cell membrane, 3) gp41 folds bringing cell and viral 
membrane close to each other, 4) gp41 forms a fusion stalk, 5) the energy derived from 
process 4 drives the hair-pin structure to form a fusion pore (Frey et al, 2006). 
   
The interaction induces a conformational change in the transmembrane protein gp41, which 
exposes the ectodomain region containing a highly hydrophobic N-terminus and two heptad 
repeat motifs (N- and C- helices). The N-terminus inserts directly into the target cell lipid 
bilayer whilst the N- and C- helices fold into a stable six-helix bundle forcing the viral and 
cell membranes into close proximity allowing membrane fusion to occur (Freed et al, 2001), 
thereby allowing the release of the viral capsid into the cell (Kilby et al, 2003; Harrison et al, 
2005). 
After internalization, there is a rapid uncoating of the capsid, by a mechanism that is less well 
understood (Ratner, 1993; Freed, 2001; Doms and Moore, 2000) but may involve both 
cellular factors and viral proteins (Sierra et al, 2005). Uncoating is followed by reverse 
transcription of the viral RNA into double-stranded complementary DNA (cDNA), a process 
mediated by RT. The enzyme catalyses DNA synthesis from 3ʹ to 5ʹ end of the RNA, initially 
producing a hybrid between the genomic RNA and the complementary DNA. The genomic 
RNA is degraded by the RNase H activity of RT generating a minus strand DNA strand 
(Freed, 2001; Coffin, 1996; Joshi, 2000). A complementary plus-strand DNA is synthesised 
by the polymerase activity of RT, resulting in the formation of a double helix DNA molecule. 
The linear double-helix DNA, together with viral proteins and enzymes and cellular proteins
 
form the pre-integration complex (PIC) (Sheehy et al, 2002; Miller et al, 1997; Jayappa et al, 
2012), which moves actively across the host nuclear membrane into the nucleus (Freed, 2001; 
Jayappa et al, 2012). 
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After nuclear import, IN catalyses the insertion of the viral DNA into the host DNA. Host 
cellular enzymes complete integration by joining the 3ʹ and 5ʹ ends of the host and viral DNA 
respectively (Freed, 2001; Engelman et al, 1991; Hindmarsh and Leis, 1999). Once 
integrated, the viral DNA remains part of nuclear DNA as provirus.  
Upon cell activation, transcription of the provirus into mRNA occurs. Transcription is 
promoted by the LTR located at the 5ʹ end of proviral DNA which has binding sites for 
cellular transcription factors including Sp1, NFᴋB, AP-1, C/EBP, and NFAT (Kilareski, 
2009; Wu and Marsh, 2003). The initial transcription process leads to the synthesis of Tat and 
Rev.  Tat in complex with TAR enhances the synthesis of RNA by pol II (Freed, 2001; 
Laspia et al, 1989) leading to the generation of three major classes of RNAs which are 
transported  into the cytoplasm: unspliced RNAs which function as mRNAs for the synthesis 
of Gag and Gag-Pol polyprotein precursors (p55 and p180 respectively) and form a dimer of 
genomic RNA that are packaged into progeny virions; partially spliced mRNAs which 
encode for Env (gp160), Vif, Vpr and Vpu  proteins; and multiply-spliced mRNAs which 
encode  for Tat, Rev,  Vpr and Nef proteins (Ratner, 1993; Freed, 2001). The splicing of the 
RNA is regulated by Rev and RRE proteins (Pollard and Malim, 1998). 
 
The env glycoprotein, gp160, is synthesised and inserted in the rough ER and transported to 
the cell surface membrane through the Golgi. During its transportation, gp160 is cleaved by 
cellular protease to generate mature gp120 and gp41. Gp41 anchors the env complex in the 
cell membrane and binds non-covalently with gp120 (Facke et al, 1993). The Gag 
polyprotein is a 53kDa precursor which has p24, p17, p9, p7, p6, SP1and SP2 domains.  Pol-
gene precursor is translated from the same transcript as Gag precursor by a ribosomal frame 
shifting mechanism (Jacks et al, 1987). This precursor is cleaved into viral enzymes 
including RT, IN, and PR. 
 
Gag and Gag-Pol polyproteins migrate to the plasma membrane and assemble to form the 
immature core of the virus. The viral enzymes, the genomic RNA dimer and the cellular 
tRNA
lys3
 then associate with the immature core (Greene, 2002; Freed et al, 1994; Bryant et 
al, 1990). During the viral assembly
 
MA forms a matrix under the viral envelope and CA 
proteins condenses to form a conical core surrounding the nucleocapsid coated genomic 
RNA. Following the assembly of viral particles specific sequences in Gag p6 promote viral 
release from the cellular surface (Gottlinger et al, 1991). During or shortly after viral release, 
PR cleaves the Gag and GagPol polyproteins precursors to generate mature Gag and Pol 
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proteins. This process in turn stimulates a series of structural rearrangement that lead to viral 
maturation (Wlodawer and Erickson, 1993). 
 
1.3 ANTIRETROVIRAL DRUGS AND THEIR MECHANISM OF ACTION. 
 
Antiretroviral drugs are classified into six major classes namely, nucleoside (or nucleotide) 
RT inhibitors (NRTIs and NtRTIs), non-nucleoside RT inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors, CCR5 antagonists, and integrase inhibitors (Table 1.1).  
 
1.3.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors  
These are nucleoside analogues that undergo intracellular phosphorylation catalysed by 
cellular kinases to generate 5ˈ triphosphate active forms (Gao et al, 1994); NtRTIs are 
already monophosphorylated and require therefore only two further phosphorylation steps to 
become active intracellularly. The phosphorylated inihibitors are then incorporated in the 
nascent viral DNA by RT, which prematurely terminates DNA chain extension (Furman et al, 
1986) due to lack of an hydroxyl group at the 3ˈ position which prevents the 5ˈ to 3ˈ 
phosphodiester bond necessary for DNA elongation (Mitsuya, 1986; Abu-ata et al, 2000).  
Drugs in this class are further categorised into thymidine and non-thymidine analogues which 
preferentially exert their antiviral activity in activated and non-activated CD4+T-lymphocytes 
respectively (Miller, 2002). Currently there are 7 N(t)RTIs approved for treatment namely, 
Zidovudine (ZDV), Didanosine (ddI), Stavudine (d4T), Lamivudine (3TC), Tenofovir 
disoproxil fumarate (TDF), Abacavir sulphate (ABC), and Emtricitabine (FTC). TDF is 
currently the only NtRTI available. 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Table 1.1 Approved antiretroviral agents available in Europe and America  
 
 
1.3.2 Non-Nucleoside Reverse Transcriptase Inhibitors  
These are a group of compounds of various structures that bind to the hydrophobic pocket 
near the catalytic site in HIV-1 RT (Grob et al, 1992) causing a distortion in the catalytic site 
that prevents RT activity due to the restriction of a flexible loop between amino acid 
positions 183 and 186 in the catalytic site. These drugs are inactive against HIV-2 
(Witvrouw, 2004). Presently approved NNRTIs are Nevirapine (NVP), Efavirenz (EFV), 
Etravirin (ETR), and Rilpivirine (RPV). 
 
 
Class Agent Abbreviation 
NRTI Abacavir ABC 
Didanosine DDI 
Emtricitabine FTC 
Lamivudine 3TC 
Stavudine d4T 
Tenofovir disoproxil fumarate TDF 
Zidovudine ZDV 
 
NNRTI Efavirenz EFV 
Etravirine ETR 
Nevirapine NVP 
Rilpivirine RPV 
 
PIs Atazanavir  ATV 
Darunavir DRV 
Fosamprenavir FOS-APV 
Indinavir  IDV 
Lopinavir/ritonavir  LPV/r 
Nelfinavir  NFV 
Ritonavir  RTV 
Saquinavir mesylate SQV 
Tipranavir TPV 
 
Fusion Inhibitors Enfuvirtide T-20 
 
CCR5 Antagonists Maraviroc MVC 
 
Integrase inhibitors Raltegravir RAL 
Elvitegravir  EVG 
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1.3.3 Protease Inhibitors  
Protease-mediated cleavage of HIV-1 polyproteins after budding is necessary for the 
maturation of HIV particles. PIs consist of compounds that bind to the active site of HIV-1 
PR thereby inhibiting maturation and resulting in the release of immature and non-infectious 
viral particles. Currently available PIs are Atazanavir (ATV), Darunavir (DRV), 
Fosamprenavir (FOS-APV), Indinavir (IDV), coformulated Lopinavir/ritonavir (LPV/r), 
Nelfinavir (NFV), Saquinavir (SQV), Ritonavir (RTV), and Tipranavir (TPV). Protease 
inhibitors are metabolised by cytochrome P-450 CYP3A4 enzyme. Ritonavir is a potent 
cytochrome P-450 CYP3A4 inhibitor (Warnke et al, 2007). Administration of PIs 
accompanied by a small dose of ritonavir increases bioavailability of other PIs  (Rathbun et 
al, 2002).  
 
1.3.4 Fusion Inhibitors 
The currently approved fusion inhibitor in Europe and America is Enfuvirtide (T20). T20 is a 
36-amino acid peptide homologous to a segment of gp41; it binds to the heptad repeat (HR1) 
domain of gp41 and blocks the formation of the 6-helix bundle hairpin structure necessary to 
pull viral envelope and host cell membrane together for fusion, thus blocking viral entry 
(Clavel and Hance, 2004). 
 
1.3.5 CCR5 Antagonists 
CCR5 antagonists are divided into large (e.g. PRO-140), medium-size (e.g. Met-RANTES) 
and small molecules (e.g., Maraviroc, Aplaviroc, Vicriviroc). Maraviroc is currently the only 
approved CCR5 antagonist. It binds to a hydrophobic pocket within the transmembrane 
region of CCR5 on the host cell membrane, causing a conformational change that prevents 
binding of the V3 stem loop of gp120 (Dragic et al, 2000).  
 
1.3.6 Integrase Inhibitors 
Integrase inhibitors that are currently approved are Raltegravir and Elvitegravir. These drugs 
inhibit the DNA strand transfer step of the HIV life cycle in two ways:  (i) have high affinity 
for the acceptor DNA site of the integrase enzyme in the pre-integration complex, competing 
with viral DNA for the binding to integrase thereby inhibiting the insertion of viral DNA into 
host cell DNA (Espeseth et al, 2000); and (ii) chelate the Mg
2+
 ion in the active site necessary 
for the activity of the integrase enzyme thereby preventing 3ˈ processing and strand transfer 
(Grobler et al, 2002). Elvitegravir must be boosted, typically with cobicistat, which has a 
mechanism of action similar to that of ritonavir.  
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1.4 HIV VIRAL LOAD TESTING 
  Figure 1.3 Kinetics of viral load and CD4 T-cell counts over 
                     the course of HIV infection 
The HIV viral load is a measure of 
the number of copies of viral RNA 
per millilitre of plasma. It provides 
an estimate of the degree of viral 
replication in vivo.  There exists 
variation in the plasma viral load at 
the different clinical stages of HIV 
infection. Viral load levels are 
highest during acute infection and 
in late stage disease (Coombs et al, 
1989; Ho et al, 1989) and are the single strongest predictor of HIV disease progression and 
death (Mellors et al, 1996; Mellors et al, 1997) (Fig. 1.3). The acute phase of HIV infection is 
characterised by a massive uncontrolled HIV replication, which results in a high viral load 
and rapid deletion of CD4+ T-lymphocytes (Cooper et al, 1985). The viral load peaks at 
about a week after primary infection (Lindback et al, 2000). During seroconversion and with 
the emergence of T-cell immune responses against HIV antigens the viral load declines 
gradually until a set-point is subsequently reached. This represents a balance between viral 
replication and immune-mediated virus clearance and remains relatively stable for months to 
years. The viral load set-point is predictive of the rate of CD4 T-cell loss, disease progression 
and mortality (Mellors et al, 1996; Touloumi et al, 1998, Lyles et al, 2000, Langford et al, 
2007). 
Baseline and follow-up measurement of viral load is important to predict the rate of decline 
in immunological strength and risk of disease progression. In addition, pre-treatment viral 
load testing is also important to decide upon initiation of antiretroviral therapy (ART) and to 
guide treatment selection. Patients with baseline viral load >100,000 copies/ml appear to 
have a greater risk of ART failure than those with lower viral load (van Leth et al, 2005). 
Certain antiretroviral agents such as abacavir and rilpivirine are especially vulnerable to loss 
of activity in patients with high viral load. Furthermore, the viral load retains its prognostic 
value during therapy, as the risk of AIDS or death in treated patients is greater in patients 
viral load >400 to 500 copies/mL while on ART (Olsen et al, 2005, Lohse et al, 2006).  
Acute HIV syndrome. Wide 
dissemination of virus. 
 Seeding of lymphoid tissue 
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During treatment, viral load determination is critical in the assessment of the efficacy of 
therapy. The goal of therapy is stated as achieving an undetectable viral load (usually <50 
copies/mL) within 24 weeks of treatment. Failure to reach this target after 24 weeks of 
therapy or subsequent rebound, constitute treatment failure (Williams et al, 2012; WHO, 
2006). Regular viral load testing is therefore necessary to detect and manage early therapeutic 
failures and prevent the emergence of drug-resistant strains. 
 
Viral load also provides a measure of infectivity and therefore the risk of transmission 
including vertical HIV transmission (Kuhn, 1997; Sperling et al, 1996; Pitt et al, 1998). In a 
prospective study of an untreated cohort, high maternal viral load was strongly associated 
with both in utero and intrapartum vertical transmission of HIV (Mock et al, 1999). 
Knowledge about maternal viral load is therefore relevant to the early initiation of mother-to-
child transmission prevention strategies. Furthermore, the viral load can be used to assess the 
risk of HIV transmission following an exposure, and decide upon post-exposure prophylaxis 
in the recipient, for example after a needle-stick injury. 
1.4.1 Techniques for HIV Viral Load Testing 
There are two major categories of HIV viral load testing techniques namely, nucleic acid 
testing (NAT) and non-nucleic acid testing (non-NAT). NAT detects and quantify viral RNA 
whereas non-NAT uses HIV viral enzymes and proteins as a correlate measure of viral RNA. 
NAT involves four major methods: Quantitative reverse transcription polymerase chain 
reaction (qRT‐PCR), nucleic acid sequence based amplification (NASBA), branched chain 
DNA (bDNA), and more recently droplet digital polymerase chain reaction (ddPCR). Of 
these, qRT-PCR is the most commonly applied methodology 
 
Real-time quantitative reverse transcription PCR 
The technique involves first the reverse transcription of HIV-RNA into cDNA. The cDNA 
then undergoes PCR-amplification, the product of which is detected and measured during 
each PCR cycle by the use of a dual-labelled oligonucleotide fluorescent probe. The probe 
has a reporter fluorescent dye at the 5ˈ end and a quencher at the 3ˈ end. The probe anneals to 
the target DNA and is cleaved by the 5ˈ nuclease activity of the polymerase enzyme during 
the PCR extension phase. Whilst the probe is annealed to the target DNA, fluorescence from 
the reporter dye is absorbed by the quencher via fluorescence resonance energy transfer 
(FRET) principle. Cleavage by the polymerase enzyme separates the reporter from the 
quencher increasing the fluorescence of the reporter.  
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For over a decade the second-generation Roche AMPLICOR Version 1.5 conventional PCR 
Assay (“AMPLICOR”) was the most widely used viral load test in both clinical trials and 
routine practice. Clinical trials used an “undetectable” viral load by AMPLICOR (below 50 
HIV-1 RNA copies/mL) as the end-point for measuring virological efficacy, and guidelines 
have adopted the same threshold as the goal of therapy. The Roche TaqMan Real-Time 
Quantitative Human Immunodeficiency Virus Type 1 RNA PCR Assay (“TaqMan”) has now 
replaced AMPLICOR in routine diagnostic settings. There are two versions of TaqMan; 
version 2 has largely replaced version 1 across Europe and has recently received FDA 
approval in the US. Other assays based on real-time PCR technology have also been 
introduced in clinical settings, including the Abbott M2000SP/M2000rt RealTime HIV-1 
Assay (“RealTime”) and the Artus HIV Virus-1 QS-RGQ Assay. The TaqMan and RealTime 
assays can be regarded as third-generation assays, characterised by high sensitivity and a 
wide-range of quantification. The assays are highly automated. They target the LTR and Gag 
region and the integrase region respectively, and have a lower limit of quantification of 40 
copies/ml (TaqMan version 1 and RealTime) or 20 copies/ml (TaqMan version 2). 
 
RealTime HIV-1 
The assay targets a conserved region in the integrase gene of HIV-1 group M and group O 
viruses (Garcia-Diaz et al, 2013). An internal control (IC) is introduced into each specimen 
during sample preparation. Purified RNA is obtained from 0.6ml of plasma using the Abbott 
m2000sp automated extractor, which employs magnetic particle technology, followed by 
amplification and detection on the Abbott m2000rt real-time PCR instrument. The duration of 
the assay is 5-6 hours, of which approximately 5 hours is hand-off during the automated 
phases of the assay. The assay lower limit of quantification is 40 copies/ml, with a dynamic 
range of 40 to 10,000,000 copies/ml (0.6 ml input). The assay was calibrated against a viral 
standard from the Virology Quality Assurance (VQA) laboratory of the AIDS Clinical Trial 
Group and against the WHO first International Standard for HIV-1 RNA (97/656).    
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1.5 HEPATITIS C CO-INFECTION IN HIV POSITIVE PATIENTS  
The most recent WHO estimate indicates that about 150 million people are chronically 
infected with hepatitis C and at least 350 000 people die from the liver disease associated 
with HCV infection each year. The hepatitis C virus (HCV) has been detected in 27% and 
25% of worldwide population with hepatocellular carcinoma and cirrhosis respectively. 
Moreover 3-4 million people are infected with the virus annually (WHO, 2012). HCV 
demonstrates a high level of geographic variability in its distribution worldwide. The highest 
prevalence rate has been reported in North Africa, particularly Egypt which has a prevalence 
rate of 15%-20 % (Alter, 2007). Moderately high prevalence between 2% and 2.9% occurs in 
Eastern Europe and Asia; low prevalence (1.0-1.9%) occurs in North America, Australia, 
Western Europe and Japan (Sheppard et al, 2005). The lowest prevalence (about 0.01-0.1%) 
has been reported from the UK and Scandinavian (Alter, 2006).  
Establishing HCV prevalence in SSA is important because the region has been historically 
estimated to have a high prevalence rate of around 5.3% (Global surveillance and control of 
hepatitis C, 1999). A review by Madhava et al, 2002, estimated an overall prevalence of 
3.0%, with highest prevalence (about 6%) in Central Africa; followed by West Africa (about 
2.4%) and eastern and southern Africa (about 1.6%).  
 
Age-related prevalence differs for various geographical locations and generally reflects 
temporal transmission patterns. For instance in Egypt, prevalence rate increases steadily with 
age with all age groups affected. This pattern shows a higher risk of infection in the distant 
past and an ongoing transmission from older to younger age groups. The existing high 
prevalence of HCV in Egypt is associated with the mass control campaign against the 
schistosomiasis, which took place between 1960 and 1980, using intravenous tartar emetic 
treatment (Strickland, 2006). The parenteral anti-schistosomal therapy (PAT) involved the 
use of reusable syringes sterilised between multiple uses which resulted in mass exposure to 
HCV infection (Frank et al, 2000). The PAT was gradually replaced with orally administered 
praziquantel in the mid 1980s. Hence, HCV prevalence is lower in children and young adults 
compared to 30 to 65 year group. 
Conversely, Australia and United States have highest infection rate among 30-49 year group 
and sharply decrease above 50 years. This pattern indicates that transmission occurred in the 
previous 20 to 40 years. A different pattern has been observed in Japan, Italy, Turkey and 
China, where infection seems to be associated with over 50 years of age indicating that risk 
of acquiring infection was highest in the past 30 to 50 years (Yen et al, 2003; Alter, 2007). 
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Infection with HCV has been associated primarily with injection drug usage (IDU), and in the 
past transfusion of infected blood and blood products. Other routes of transmission include 
organ transplantation from infectious donors; medical, surgical or other interventions with 
contaminated needles and equipment; haemodialysis; occupational exposures to contaminated 
needles and equipments; and uncommonly mother-to-child transmission and sex with an 
infected partner. Among these factors, IDU, transfusion, and usage of contaminated needles 
or equipment are culpable for most infections worldwide. Appreciably high seroprevalence 
rates have been reported to occur in injecting drug users in USA (30%), Europe (44-80%) and 
Asia (36-75%) (Sy and Jamal, 2006; Alter, 2007). Screening of blood and blood products has 
helped to virtually eliminate transmission by this route in resource-rich countries and 
worldwide (Busch et al, 2005). 
It is estimated that 4-5 million out of the 40 million persons infected with HIV are chronically 
infected with HCV (Alter et al, 2006). The number of persons with HIV/HCV co-infection 
differs for various geographical areas but it is generally influenced by the predominant 
effective route of HIV transmission in a subpopulation. HIV/HCV co-infection prevalence is 
high among populations where IDU is the predominant mode of HIV transmission. On the 
other hand, HCV prevalence is low among populations where sexual exposure is the major 
mode of HIV transmission. For example it is estimated that 72-95% of HIV positive injecting 
drug users are chronically infected with HCV, although HIV prevalence among this 
subpopulation is low.  In addition, a HCV prevalence of up to 27% has been described among 
HIV positive MSM and heterosexuals (Sheppard et al, 2005; Alter, 2006). HCV prevalence 
among a cohort of HIV-positive haemophiliacs ranged between 92-100% (Francois, 2002; 
Shepard et al, 2005). In sub-Saharan Africa where HIV transmission is largely through sex and 
mother-to-child transfer, HCV occurs in about 3% of HIV infected patients (Ocama and 
Seremba, 2011). 
 
Studies have shown that HIV/HCV co-infected patients have higher plasma HCV RNA 
levels, accelerated development of liver fibrosis, increased risk of cirrhosis development, 
high risk of hepatocellular carcinoma and increased mortality rate compared to HCV mono 
infected patients (Sherman, 2005; Operskalsky and Kovacs, 2011; Benhamou et al, 2001; van 
de Laar et al, 2010). Conversely, ART has been found to moderate progression of HCV-
related liver disease hepatitis. HIV also appears to increase the risk of perinatal transmission 
of HCV (Gibb et al, 2000). 
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There are conflicting reports on the effect of HCV on the natural history of HIV. While some 
studies associate HCV infection with increased AIDS and mortality risk and decreased CD4 
recovery on ART (d’Arminio-Monforte et al, 2009; Greub et al, 2000; Shepard et al, 2005), a 
publication from the USA found no difference in HIV disease progression and survival and 
immunological response to ART between HIV-infected and HIV/HCV co-infected patients 
(Sulkowski et al, 2002).  The mechanism by which HCV impacts on HIV disease progression 
in co-infection is believed to involve increased T-cell activation and CD4 T –cell apoptosis 
leading to immunological dysfunction (Operskalski et al, 2011; Kaufmann et al, 2003). 
 
1.6 METHODS OF HCV DETECTION  
The laboratory methods used for the diagnosis of HCV infection can be placed into two main 
categories: 
1. Serological assays to detect anti-HCV antibodies or HCV proteins in serum or 
plasma.  
2. Molecular assays to detect, quantify and type HCV RNA. 
 
1.6.1  Timeline and Significance of HCV Diagnostic Markers 
 
After initial exposure, HCV RNA can be detected in blood within 1-3 weeks and is present at 
the onset of symptoms. Antibodies to HCV can be detected in only 50-70% of patients at the 
onset of symptoms, but in >90% after 3 months. Following acute infection, if HCV RNA is 
still present at 6 months after infection, the likelihood of spontaneous HCV clearance is 
extremely low, and the patient is diagnosed with chronic infection. In patients with chronic 
HCV infection, the HCV RNA load predicts responses to antiviral therapy and measures the 
success of treatment.  
If a patient is HCV antibody positive but HCV RNA negative, the patient has cleared the 
HCV and does not have chronic HCV infection. In HIV-infected patients, the HCV antibody 
test result sometimes is falsely negative even in chronic infection; therefore, if HCV infection 
is suspected the HCV RNA is tested. 
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1.6.2 Serological Assays for Anti-HCV Antibody Detection 
 
Enzyme Immunosorbent Assays (EIA) 
Three generations of screening EIAs that detect antibodies against various HCV epitopes 
have been developed. First generation EIAs (EIA-1) were developed in the late 80s and 
targeted the c100-3 epitope of the HCV NS4 protein; the assays had limited sensitivity and 
specificity (Kuo et al, 1989, Gretch, 1997). Second-generation EIAs (EIA-2) were introduced 
in the early 90s; they contained multiple HCV antigens from the NS3 (c33c) and core l (c22-
3) regions, resulting in improved sensitivity. This shortened the average ‘window period’ for 
seroconversion after transfusion as it detected HCV antibodies sooner than EIA-1, but 
specificity remained relatively low (Richter, 2002; Kolho, 1992).  In the late 90s third 
generation EIAs (EIA-3) were introduced that contained reconfigured core, NS3 and NS4 
antigens plus NS5 antigen; this further improved sensitivity of detection in early infection 
(Barrera, 1995; Kao et al, 1996). It should be noted however that there remains a window 
period of several weeks (around 6 weeks) between HCV infection and seroconversion, which 
may lead to negative antibody results with positive HCV antigen or RNA detection soon after 
infection (Cox et al, 2005; Stramer et al, 2004). 
 
Supplemental tests  
HCV EIA tests may represent false positives (Hoslina et al, 2012). A supplemental test is 
required to confirm seropositivity in patients who are HCV RNA negative.  A second and 
third generation recombinant immunoblot assays (RIBA) were approved in 1993 and 1999 
respectively by the FDA. The immunoblot is a strip immunoassay which includes the core 
antigen (c22p), NS3, NS4, without (in second generation) or with NS5 (in third generation) 
recombinant proteins plus human superoxide dismutase to detect nonspecific antibodies. 
Results could be negative, positive or indeterminate. With RIBA, about 95% EIA positive 
results are confirmed. However in low prevalence blood donors, confirmation is about 50% 
(Leon et al, 1998). RIBA indeterminate results can temporally occur in seroconversion stage 
(Ritcher, 2002).  
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1.6.3  Molecular Assays  
Molecular assays are categorised into qualitative or quantitative assays and are used to detect 
or quantify the viral RNA. The most common tests use real-time reverse transcriptase PCR 
and several commercial and in house assays have been developed with variable lower limit of 
quantification. There are currently three tests commonly: real-time reverse transcription 
polymerase chain reaction (RT-PCR); branched-chain DNA (b-DNA); and transcription 
mediated amplification (TMA). bDNA test is less sensitive than RT-PCR and TMA, which 
can show a lower limit of quantification of 5-10 IU/mL.  
 
1.6.4 Genotyping 
HCV is genetically heterogeneous with at least six known genotypes. Determination of 
genotypes is relevant in predicting the success of antiviral therapy (Schiff et al, 1999). 
Techniques for HCV genotype determination entail screening test that detects point mutations 
within HCV genome and confirmatory test that evaluate larger segments of HCV genes. 
Several HCV genotype screening assays have been described and include reverse 
hybridization line probe assay (LiPA, Innogenetics, Zwijnaarde, Belgium), restriction 
fragment length polymorphism (RFLP) of the PCR amplicons, and nested PCR with 
genotype-specific parameters to the core region. The optimal genotyping region is reported to 
be the 5ˈ untranslated region (UR) because of high intra genotype conservation, but 
considerable variation between genotypes (Schiff et al, 1999).  Gold standard confirmatory 
tests for HCV genotype determination include nucleotide sequencing and phylogenetic 
analysis of the E1 gene or NS5B gene. 
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1.6.5 Typical HCV Testing Algorithm 
Figure1.4 shows the standard testing algorithm for HCV as recommended by the WHO, CDC 
and The UK Standards Unit, Microbiology Services Division. 
Figure 1.4 Flow chart of HCV testing algorithm  
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1.7 HEPATITIS C CORE ANTIGEN AS A MARKER OF HCV REPLICATION 
Though HCV antibody testing has been useful in diagnosing HCV infection and reducing 
viral transmission through transfusion, it is associated with lack of the ability to confirm viral 
infection during the pre-seroconversion window phase and in some immunocompromised 
patients. Molecular assays have contributed to the solution to this problem but results are 
obtained at a high cost and require considerable infrastructure and skill. HCV core antigen 
(HCVcAg) testing presents an alternative to nucleic acid testing for the purpose of early HCV 
detection (Zhang et al, 2007; Aoyagi et al, 1999; Icardi et al, 2001, Kobayashi et al, 1998), 
monitoring antiviral therapy and reoccurrence of HCV infection after liver transplant, and 
screening of dialysis patients, due to its strong correlation with HCV RNA levels (Tanaka et 
al, 1996; Park et al, 2010; Bouvier-Alias, 2002; El- Shaarawy et al, 2007; Kawai et al, 2002).  
 
Early HCVcAg assays (Takahashi et al, 1992; Moriya et al, 1994) were found to be 
insufficiently sensitive. Subsequent assays used different antibodies (e.g., targeting amino 
acid residues 21-60), which improved sensitivity (Kashiwakuma et al, 1996). A first 
generation commercial HCVcAg assay was developed by Ortho Clinical Diagnostics, 
Raritan, NJ which utilized the 5F11 and 5E3 monoclonal antibodies for the capturing and 
detection of core antigen, respectively. The lack of its ability to detect antibody-bound 
antigen led to the production of a second generation assay referred to as Total HCV Core 
Antigen ELISA Test System or trak-C assay (Ortho Clinical Diagnostics). Improvement over 
the first generation was achieved by incorporating a sample pre-treatment procedure to 
dissociate core antigens form core antigen–anti-core antibodies complex; using two capture 
monoclonal antibodies (C11-3 and C11-7) and two horseradish peroxidise-conjugated 
monoclonal antibodies (C11-10 and C11-14) for the detection of the bound HCV core 
antigen.  
 
The sensitivity and specificity of various in-house and commercial HCV core antigen EIA 
assays have been evaluated by comparing results with NAT. Kawai et al, 2002 showed that 
the sensitivity of an in-house HCVcAg assay was lower than that of the Cobas Amplicor 
HCV Monitor 2.0; however, the HCVcAg levels correlated significantly with the HCV RNA 
levels. Other investigators (Icardi et al, 2001; Widell et al, 2002; Letowska et al, 2004; 
Gaudy et al, 2005; El-Shaarawy et al, 2007) obtained sensitivity of 95% to 99.3% and 
specificity of 94.2% to 99.9% with the Ortho Antibody to HCVcAg ELISA Test System. 
Other authors however (Reddy et al, 2006) described less favourable performance, with 
lower sensitivity and specificity (60% and 83% respectively) and a very low positive 
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predictive value (PPV, 14%) with the same HCV RNA and HCVcAg testing protocols. 
Among the factors which probably contributed to the difference in sensitivity and specificity 
may include difference in HCV genotypes. Assay sensitivity can be affected by sequence 
heterogeneity of the core protein (Saeed et al, 2009). Therefore the ability of the assay to 
detect HCV genotypes and subtypes relies on the anti-HCV core antigen capture or detection 
antibody used. Various studies however have reported that HCVcAg detection correlates with 
plasma HCV RNA levels irrespective of genotype (Kawai et al, 2002; Bouvier-Alias et al, 
2002; El-Shaarawy et al; 2007, Park et al, 2010). Overall, it has been found that HCVcAg 
assays detects core antigen when HCV RNA levels are above about 20,000 IU/mL (Bouvier-
Alias et al, 2002). 
 
1.8 HIV AND HCV INFECTION IN GHANA  
1.8.1 HIV Prevalence  
 
Figure 1.5 A map showing the ten regions of Ghana. 
Ghana has a generalised epidemic with a prevalence of 
2.1% according to the 2011 sentinel survey report 
(Ghana AIDS commission, 2012). It is estimated that 
80% of infection in Ghana occur through sexual routes 
(Ghana AIDS commission, 2012).The most affected 
age group is 30-34 years of age with a prevalence of 
2.9% in 2011. Prevalence shows geographical 
differences ranging from 0.3% in the Northern region 
to 4.7% in the Central region. The most urbanised 
areas – namely the Greater Accra Region and the 
Ashanti Region – had a prevalence of 3.2% and 3.1% 
respectively in 2011. This compared with prevalence 
below 0.4% in rural communities (Ghana AIDS 
commission, 2012). 
 
 
 
 
19 
 
1.8.2 Antiretroviral Therapy  
ART was introduced in the country in 2003 and overall, a total of about 65 000 people living 
with HIV have received treatment since the onset of the programme and about 56 000 adults 
and 3000 children are still receiving therapy. As of 2011, close to 4 000 men and 10 500 
women were on ART together representing about 60% of those who need ART (Ghana AIDS 
commission, 2012). There are currently over 150 treatment centres nationwide which comply 
with a national guidelines (National HIV/AIDS/ STI Control Programme - Ghana, 2010). 
The current antiretroviral drugs recommended in Ghanaian national guidelines for HIV 
treatment are as follows:  
1. NRTIs and NtRTIs: Zidovudine, Lamivudine, Abacavir, Emtricitabine 
2. NNRTIs: Nevirapine, Efavirenz 
3. Pis: Ritonavir boosted Lopinavir (LPV/r) ritonavir boosted Atazanavir (ATV/r). 
 
The regimens indicated for treatment includes 2 NRTIs and 1 NNRTI; or 2 NRTIs and 1 
ritonavir boosted PI. Table 1.2 shows the choice of drugs used as first and second line as 
recommended by the national guideline. 
 
Table 1.2 Recommended antiviral combinations for HIV treatment in Ghana  
FIRST-LINE 
First Choice  
ZDV + 3TC + NVP or EFV 
 
Second Choice 
 
First option: TDF + (3TC or FTC) + NVP 
SECOND LINE 
         First Choice TDF+ FTC or 3TC + (LPV/r or ATV/r) 
        Second Choice ZDV+3TC+ (LPV/r or ATV/r) 
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1.8.3 Treatment Monitoring  
Monitoring of ART in Ghana as indicated in the national guideline involves: 
1. Clinical evaluation to be done at 2-3 months during follow-up to monitor adherence, 
drug toxicity, allergies, adverse effects, opportunistic infection and efficacy of 
therapy. Laboratory monitoring to be conducted every 6 months during follow-up to 
establish side effects and drug toxicity: includes haematological test (full blood 
count); urine routine examinations; biochemistry (fasting blood sugar, 
BUE/Creatinine, AST, ALT, and lipid profile); microbiology (sputum test for AFBs 
to rule out TB infection if symptoms of respiratory infection are observed); 
immunological assessment (CD4 T-cell count). 
 
 Viral load testing is recommended before and at every six months of therapy. 
However, routine viral testing is not available at the majority of treatment centres due 
to lack of laboratory facilities and funds. Finally, tests for diagnosing viral hepatitis 
are only recommended for the purposes of ruling out liver damage attributable to 
ART.  
 
1.8.4 HIV/HCV Co-Infection  
Data on the prevalence of HCV among HIV positive patients in Ghana are limited. HCV 
seroprevalence of 3.6% and 17% (2/12) has been reported among ART-naive adults and 
women who visited the obstetrics and gynaecology unit, respectively at Korle-Bu Teaching 
hospital (KBTH) in Accra (Sagoe et al, 2012; Apea-Kubi et al, 2006). A definitive HIV/HCV 
co-infection prevalence rate in a Ghanaian cohort is yet to be published. No treatment 
algorithm is presently adopted for the treatment of HIV/HCV co-infection in Ghana. 
Therefore accessing treatment outcomes in Ghanaian HIV/HCV cohort will be necessary to 
provide basis for a review of treatment protocols for coinfected patients. 
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1.9 The Kumasi HIV Cohort 
The Kumasi cohort consists of adult HIV positive patients who were attending the Komfo 
Anokye Teaching Hospital (KATH) HIV clinic for routine medical care. Kumasi is the 
capital city of the Ashanti Region and the second largest city of Ghana. Of the 4 million 
people in the Ashanti region (Ghana Statistical services, 2010), 3.1% are estimated to be 
living with HIV (Ghana AIDS commission, 2012) and the major treatment centre is KATH in 
Kumasi.  ART was introduced at KATH in 2004 and over 7000 patients have since been 
enrolled of which over 3000 are currently receiving therapy. The adult clinic runs weekly 
seeing an average of 100 patients per day and between 700 and 1000 newly diagnosed 
patients annually. 
 
Adult treatment and treatment monitoring at KATH HIV clinic are in compliance with the 
National HIV Treatment Guidelines (National HIV/AIDS/ STI Control Programme-Ghana, 
2010). Treatment monitoring involves clinical evaluation and CD4+ cell count as a measure 
of treatment efficacy, and full blood count, creatinine and hepatic transaminases (AST/ALT) 
to detect treatment toxicity. Though recommended by the national guidelines, HIV viral load 
testing is not included in the routine monitoring of HIV patients in Kumasi. 
 
Whereas HBV prevalence has been well characterised in Kumasi HIV patients (Geretti et al, 
2010) data on the prevalence of HCV in co-infected patients is currently limited in Kumasi as 
in the rest of Ghana. Although diverse HCV seroprevalence rates ranging from 0.5% to 
18.7% have been published among different Ghanaian populations (Sagoe et al, 2012, Apea-
Kubi et al, 2006, Acquaye et al, 2000, Owusu-Ofori et al, 2005, Nkrumah et al, 2011), the 
rate of HCV co-infection among HIV positive patients in Kumasi is currently unknown. The 
diverse seroprevalence rates reported may be due to the various populations studied but 
potential differences in the specificity and sensitivity of the anti-HCV screening assays 
employed cannot be ruled out. Typically the available studies did not employ HCV RNA 
detection or RIBA for the confirmation of infection or antibody positivity. 
 
As more patients benefit from the scale up of ART in Ghana, the implication is that life 
expectancy in patients with chronic viral hepatitis will be improved and the evaluation of the 
overall burden of co-infection becomes critical. Given the limited infrastructure, there is also 
a need to evaluate screening assays that can provide a specific diagnosis of HCV infection 
and guide appropriate treatment strategies for HIV/HCV co-infected patients in Ghana.  
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1.10 AIMS OF THE STUDY 
 
The aim of this project was to develop serological and molecular skills that can be transferred 
to Kumasi, Ghana in order to improve the care of the local HIV-infected population. The 
serological and molecular skills were applied to identify HBV co-infection and determine 
ART outcomes in the Kumasi cohort, and to evaluate the best approach for diagnosing HCV 
co-infection in the same population.  
 
1.11 OBJECTIVES 
 Become proficient in HIV viral load testing.  
 Become proficient in HCV serology testing. 
 Describe the HIV virological response in the Kumasi cohort.  
 Determine the performance of HCV antibody screening assays in relation to HCV 
PCR results. 
 Develop an EIA to detect HCV core antigen as an alternative to HCV RNA testing in 
Ghana. 
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CHAPTER TWO – MATERIALS AND METHODS 
 
2.1 STUDY SITE  
Figure 2.1 The study area and site 
The study site is the HIV clinic at Komfo 
Anokye Teaching Hospital (KATH) in Kumasi, 
the second largest city in Ghana located in the 
Ashanti Region, which is approximately 300 
miles north of the equator. KATH is a thousand- 
bed teaching hospital which administratively 
consists of eleven directorates. The HIV clinic at 
KATH is under the Medicine Directorate and it 
is one of the major HIV treatment centres in 
Ghana in terms of numerical status of clients and 
infrastructure. After clinical evaluation and 
treatment monitoring at the clinic, patients are 
sent to the Diagnostics Directorate for laboratory 
services. Laboratory services available at KATH 
include HIV serology, CD4 cell count, 
biochemistry, microbiology, haematology, and 
radiology. 
 
2.2 STUDY POPULATION 
Consecutive adult HIV seropositive patients who attended the KATH HIV clinic for routine 
medical care between October 2010 and June 2012 and consented to take part in the ‘HEPIK’ 
study (HIV and viral hepatitis study in Kumasi) were prospectively recruited in this study.  
Demographic and clinical data were extracted from the clinical record files. Serum and 
plasma samples were collected and stored at -80˚C at KATH. In addition to undergoing local 
testing, frozen serum and plasma on dry ice and dry plasma spots (DPS) were shipped to the 
University of Liverpool (UoL) for additional investigations. 
Ethical approval was obtained from the Committee on Human Research Publications and 
Ethics at the Kwame Nkrumah University of Science and Technology of Kumasi, Ghana. 
 
Komfo Anokye Teaching           
Hospital 
Location of the study area 
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2.3 SAMPLE COLLECTION AND STORAGE 
2.3.1 Plasma and Serum Samples 
Two trained phlebotomists at KATH took venous blood into serum and EDTA tubes labelled 
with study identification information and were taken to the ‘HEPIK’ laboratory for testing 
and storage. The samples were spun at 3000 rpm for 10 minutes to obtain the supernatant 
serum and plasma. The recovered serum and plasma were aliquoted into cryovials and stored 
at -80˚C. Four cryovials each were used to store the plasma and serum per patient to avoid 
freeze-thawing of a particular sample. 
 
2.3.2 Dry Plasma Spots Preparation 
Dry plasma spot (DPS) samples were prepared from stored plasma at KATH using Whatman 
903 protein saver cards according to the following procedure: 
1. Frozen plasma was thawed at room temperature for 30 minutes.  
2. The working surface was decontaminated with 70% ethanol and Whatman cards were 
labelled with sample identification details.  
3. The sample was vortexed for 6 seconds. 
4. Using a micropipette with filter tips, 75µl of plasma was applied to the centre of each 
of 4 pre-printed circles on the card, making sure that cards from different patients do 
not come into contact with each other and tips were changed after producing each 
card. Care was also taken avoid touching the cards with pipette tips when dispensing 
the serum. 
5. The cards were placed face up on dry, ant-free surfaces to dry at room temperature 
overnight. 
6. The dry cards were closed such that the dry spots faced inside.  
7. Each DPS was placed in a single dry plastic bag together with three desiccant sachets. 
The bag was squeezed to displace air and then sealed. 
8. Sealed bags were stored in a dry box and transported to Liverpool within 1 week after 
preparation. At UoL the DPS were stored at -80˚C. 
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2.4 LABORATORY TESTS 
The following assays were performed (location; person performing the experiments): 
 
1. Hepatitis B surface antigen (HBsAg) testing (KATH; KAA) 
2. Hepatitis C antibody testing (KATH and UoL; KAA). 
3. HIV-1 RNA load testing (UoL, KAA)  
4. HCV RNA testing (UoL, Simon King).  
2.4.1 Hepatitis B Surface Antigen Testing  
Samples were screened for HBV surface Antigen (HBsAg) using the Determine HBsAg 
lateral flow test (Inverness Medical, Japan) HBsAg. The Determine test was previously 
shown to have excellent specificity but relatively low sensitivity in the Kumasi HIV-infected 
population (Geretti et al, 2010). Therefore, samples that tested HBsAg negative by Determine 
were retested by the Murex HBsAg 3.0 EIA (Abbott Diagnostics Division, UK). 
Determine assay 
Determine HBsAg is an immunochromatographic test for qualitative detection of HBsAg. 
Freshly collected serum (50µl) is added to the sample pad on the test card. The sample mixes 
with the selenium colloid-antibody (mouse, monoclonal) conjugate as it migrates through the 
conjugate pad. The mixture then migrates through immobilised antibody at the patient 
window site. If present, HBsAg in the sample binds to the antibody-selenium colloid and to 
the antibody at the patient window site forming a red band at the patient window site. If 
absent the conjugate flows past the patient window and no red band is formed at the patient 
window site. A red line is formed at the control window site to validate assay. Results are 
read 15 minutes after serum application. Red bars appearing on both patients and control 
window sites were interpreted as positive whereas only one red bar at the control site was 
interpreted as negative and no bar at both sites was interpreted as invalid.  
Murex HBsAg EIA 
The sample is pre-incubated in coated microwells with a mixture of mouse monoclonal 
specific for different epitopes on the ‘a’ determinant of HBsAg. Affinity purified goat 
antibody to HBsAg conjugated to horseradish peroxidase is then added to the sample in the 
well. During the two incubation steps any HBsAg present in the sample is bound to the well 
in an antibody-antigen-antibody-enzyme complex. After washing, a solution containing 
3,3ˈ,5,5ˈ-tetramethylbenzidine (TMB) and hydrogen peroxide is added to the wells. Wells 
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which contain HBsAg and hence bound conjugate will develop a purple colour which is 
converted to orange when the enzyme reaction is terminated with sulphuric acid, and colour 
absorbance is read at 450nm. 
The main steps in the assay were: 
1. 25 µl of sample diluent added to each well and 75µl of sample were added to each 
well.  
2. After changing the gloves, 2 negative controls (NC) and 1 positive control (PC) were 
added to the wells 
3. The plate was incubated  at 37˚C for 60 minutes 
4. 50 µl of conjugate was added to each well and the plate was rocked gently for 10 
seconds, followed by incubation at 37˚C for 30 minutes. 
5. The plate was washed in 5 cycles to remove unbound components. 100 µl of freshly 
prepared substrate was added to each well, followed by incubation for 30 minutes at 
37˚C. 
6. The reaction was stopped with 50 µl of sulphuric acid and the absorbance of each well 
was read at 450nm wavelength. 
 
Absorbance cut-off value (COV) was calculated as follows: 
COV = Mean NC absorbance + 0.05 
 
 
Samples with absorbance below and above 10% of the COV were recorded as non-reactive 
and reactive respectively, whereas absorbance within +/- 10% COV was recorded as 
equivocal. Equivocal samples were retested. The assay was accepted as valid if the NC 
absorbance was less than 0.2 and the PC absorbance was greater than 0.8. 
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2.4.2 Hepatitis C Antibody Testing  
Serum samples were obtained from the Kumasi cohort and tested for HCV RNA by Simon 
King (PhD student in the group). Samples with known HCV RNA status – either positive or 
negative – were included in the HCV serology study. Four assays were employed which 
included two automated assays, the Abbott Architect anti-HCV (Abbott Diagnostics) and the 
Vitros Anti-HCV assay (Ortho Clinical Diagnostics), and two manual plate EIAs, the 
Monolisa HCV Ag-Ab ULTRA (BIO-RAD) and the ORTHO HCV 3.0 ELISA System with 
Enhanced SAVe (Ortho Clinical Diagnosis). The Architect and VITROS assays were 
performed in London by the diagnostic staff of the NHS virology laboratories of Charing 
Cross Hospital, and the Royal Free NHS Foundation Trust, respectively. 
 
Architect anti-HCV assay 
The assay is an automated two-step chemiluminescent microparticle immunoassay for the 
detection of serum or plasma anti-HCV antibodies. If antibody is present in the sample, it 
binds to a solid phase made of recombinant HCV antigen coated paramagnetic particles. 
After a wash step, a murine anti- human IgG/IgM acridinium-labelled conjugate is added. 
Following a further wash, hydrogen peroxide and sodium hydroxide are added. The resulting 
chemiluminescent reaction is measured in relative light units (RLU) which are directly 
proportional to the amount of anti-HCV present in the sample.  
The assay cut-off is computed using the mean RLU of a triplicate of the manufacturer’s 
calibrator which is included during the assay. The assay cut-off is calculated by adding 0.074 
to the mean RLUs of the calibrator. 
Results are calculated as signal/cut-off (S/C) value. 
Result (S/C) =  
                      
             
   
Specimens signal to cut-off ratio (S/CO) values <1 are considered non-reactive whereas 
S/CO values ≥1 are considered reactive. Results of S/C ≥ 0.9 but <1.0 are classified as 
equivocal. 
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VITROS anti-HCV assay  
The VITROS anti-HCV test is performed on the VITROS Eci/EciQ Immunodiagnostic 
System, the VITROS 3600 Immunodiagnostic System and the VITROS 5600 Integrated 
System using Intellicheck
®
 Technology. The assay involves a two-step immunometric 
technique which involves the binding of HCV antibody to HCV recombinant antigen–coated 
wells at the first stage. Following a washing step which removes the unbound sample, a HRP-
labelled murine monoclonal anti-human IgG conjugate binds to any human IgG bound to the 
wall. After removal of unbound conjugate by washing, a luminogenic substrate is added to 
the wells followed by the addition of an electron transfer agent. The HRP catalyses the 
oxidation of the luminal derivative and the intensity of the emitted light is increased and 
prolonged by the electron transfer agent. The light signal is read by the system which is a 
measure of the amount of HRP conjugate bound which in turn directly correlates with the 
concentration of the anti-HCV present in the sample. The instrument is calibrated prior to 
testing using a calibrator supplied by the manufacturer. During the calibration process, a lot-
specific parameter is used to determine a valid stored cut-off value for the VITROS 
Immunodiagnostic System. Results are calculated as signal/cut-off (S/C) value.  
 
Result (S/C) =    
                      
             
 
A result of <0.9 S/C is interpreted as non-reactive whereas a result of ≥ 1.00 S/C indicates 
reactive for anti-HCV. Results of S/C ≥ 0.9 but <1.0 are classified as equivocal. 
 
Monolisa HCV Ag-Ab ULTRA  
The assay involves initial addition of conjugate 1, which contains biotinilated monoclonal 
anti-HCV capsid, and samples/controls to the wells. The solid phase of is coated with 
monoclonal anti-capsid antibodies, 2 recombinant proteins from NS3 1 and 3a, one 
recombinant antigen from NS4 region and a mutated peptide from the capsid area of hepatitis 
C genome. If present, anti-HCV antibodies bind to antigens fixed on the solid phase and 
capsid antigens bind to the monoclonal antibodies coated on the microplate and the 
biotinilated capsid antibody. After incubation and washing peroxidase labelled antihuman 
IgG and Streptavidin-peroxidase conjugate are added. Streptavidin peroxidase conjugate 
reacts with biotinilated monoclonal antibodies against HCV capsid antigen if present. This 
reaction takes place at 37˚C for 30 minutes and a washing step removes all unbound 
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enzymatic conjugate and the antigen-antibody complex is detected by the addition of 
substrate (citric acid and sodium acetate solution plus TMB). The reaction is stopped with 1N 
sulphuric acid and absorbance read at 450nm. The assay was carried out with adherence to kit 
SOP as follows. 
1. 100µl of conjugate 1 was added to the formatted microplate and 50 µl of samples 
were added to the wells starting from the sixth well and the reaction mixture was 
homogenised by 5 time aspiration with the micropipette. 
2. With new gloves on, one negative control, 3 antibody positive and 1 antigen positive 
controls were sequentially added to the plate starting from the first well. 
3. The microplate was covered with adhesive sealer and incubated for 90 minutes at 
37˚C. The microplate was then washed in 6 cycles with working concentration of 
washing buffer. 
4. 100 µl of conjugate 2 was dispensed into each of the wells and the plate was covered 
and incubated at 37˚C for 30 minutes. The plate was washed in 6 cycles with washing 
buffer. 
5. 80 µl of freshly prepared TMB substrate was applied to each well. Then 100 µl of 
stop solution was added to the wells to stop the reaction. 
6. The absorbance of the wells was then read at 450nm using Mutiscan Spectrum, 
Thermo Electron Corporation, Thermo fisher, UK (SR# 1588-522) within 30 minutes 
of stopping the reaction. 
The optical densities of the three positive antibody controls (PabC) were used to calculate 
COV by the following equation. 
 
COV=   
             
 
       
The following assay validation criteria were used based on the assay protocol. 
1. Negative control absorbance less than 0.6 x COV 
2. 0.8 <mean absorbance of PAc ≥ 2.400 
3. Absorbance of antigen positive control greater than 0.5 
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2.4.3 Analysis  
True positivity was defined as a sample reactive by the EIA and HCV-RNA positive or HCV-
RNA negative but positive by Architect whereas true negative sample was defined as 
negative by the EIA and negative by PCR or Architect. HCV-RNA and Architect results were 
used as reference because HCV-RNA testing is the gold standard for HCV diagnosis and 
Architect has been validated to have highly sensitive and specific in the UK (HPA-MiDAS & 
NBS-NTMRL, 2008).  Sensitivity, specificity, negative predictive value (NPV) and positive 
predictive value (PPV) of each the Vitros, Monolisa and Ortho were calculated using the 
following formulae: 
Sensitivity = 
                        
                                               
   
 
Specificity = 
                       
                                               
  
 
          NPV= 
                         
                                                 
 
 
           PPV =  
                         
                                                 
 
 
 
Samples with absorbance less than 10% of COV were negative whereas samples with 
absorbance greater than 10% COV were considered positive. Signal to cut-off ratio (S/CO) 
for each sample was calculated by dividing sample absorbance by the COV.  
 
2.4.4 Real-Time PCR for Serum/DPS HCV-RNA Determination 
The process involved off-board lysis of HCV in serum and DPS and internal control (Phocine 
Distemper Virus, PDV), automated extraction of HCV-RNA using NucliSENS
®
 easyMAG 
automated Extractor (Biomerieux SA, France) and Real-Time PCR determination of HCV-
RNA load using ABI Prism 7500 Real Time PCR System. 
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2.4.5 Plasma HIV-1 RNA Load Testing 
The process involved the following steps: 
1. Automated HIV-1 RNA extraction and master mix preparation using Abbott m24sp™ 
System (Abbott Molecular Inc. USA) and Abbott m2000sp™ System (Abbott 
Molecular Inc. USA). 
2. Real-Time PCR on Abbott m2000rt Instrument System (Abbott Molecular Inc., 
USA). 
HIV-1 RNA extraction  
System specific reagents used were: 
1. Abbott m™ Sample preparation System, which comprises:  
a. Lysis buffer (100mM Tris solution containing Guanidine thiocyanate and 10% 
Tween) 
b. Wash buffer 1 (50mM Acetate solution containing Guanidine thiocyanate and 
detergent)  
c. Wash 2 (Nuclease free water) 
d. Elution buffer (20mM Phosphate buffer solution with preservative) 
e. Microparticles (1.5% Maghemite (g-Fe2O3) particle in Lysis buffer) 
2. Internal control (IC), controls (negative, low positive and high positive) and 
calibrators  
Lysis buffer containing the GITC lyses viral particles by denaturing the capsid and 
inactivating RNAses whereas the Tween detergent destroys the membrane proteins. The 
negatively charged viral RNAs are released which are captured by positively charged 
magnetic particles under a basic and high salt concentrated medium. The magnetic particle-
RNA complex are captured in a magnetic field and are washed efficiently using wash buffer 
1 and 2 to remove cell debris and proteins.  The elution buffer containing negatively charge 
phosphate competitively removes RNA from the Fe
2+
 magnetic particles. 
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Sample preparation  
1. Plasma sample, IC, calibrators and controls were removed from freezer and allowed 
to thaw to room temperature. 
2. Instrument daily maintenance was performed which included nucleic acid 
decontamination and disinfection of instrument platforms, and extensive flush to 
remove trapped air bubbles in fluidic system.  
3. Sample tubes were labelled with respective sample ID. 
4. The samples and controls were vortexed for 6 seconds to homogenise. 
5. 1 mL of the plasma was aliquoted into the sample tubes and centrifuged for 5 minutes 
at 3000rpm. 
6. The samples and controls were appropriately arranged in sample racks according to 
the instrument protocol. 
7. Reagents were loaded onto the machine in appropriate positions. 
8. Samples and control positions were appropriately assigned and machine was started to 
run extraction. 
Master Mix Preparation 
System specific reagents used were Abbott Real-Time Amplification reagents comprised: 
 
a. A thermostable rTth DNA polymerase enzyme (rTth polymerase) 
b. Activator reagent which contains 30mM manganese chloride solution 
c. Oligonucleotide reagent which contains 4 primers, 2 probes, 1 quencher 
oligonucleotide and 4dNTPs in a buffered solution, with a reference dye. 
 
Master mix was manually made up for the Abbott m24sp by putting together per sample 
11.29µl, 39.54 µl and 5.88 µl of activator reagent, oligonucleotide reagent and rTth 
polymerase respectively. Master mix preparation was an automated process on the Abbott 
m2000rt. At the end of the process 50µl of RNA extract was added to 50 µl master mix in a 
96-well optical plate. The plate was sealed with optical plate adhesive sealers and transferred 
to the Abbott m2000rt instrument for viral load testing by Real-time PCR.  Abbott m24sp and 
m2000sp instruments used the Evoware and m2000sp v5.0.186.0 software respectively to run 
extraction and master mix preparation. New instrument calibration was run each time there 
was a change in lot numbers of sample preparation and amplification reagents 
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2.5 HEPATITIS C CORE ANTIGEN ELISA DEVELOPMENT 
2.5.1 Reagents  
Reagents used for the HCV core antigen ELISA development are indicated in Table 2.1. In 
order to develop a HCV Ag EIA, a literature search was performed and the format as 
indicated by Kawai et al (2002) and Aoyagi et al (1999) were initially considered. The format 
was that of a direct sandwich EIA, comprising a monoclonal capture antibody bound to the 
plate and a labelled monoclonal secondary antibody for detection. An indirect sandwich 
method was explored for its effects on the sensitivity and specificity of the assay. The assay 
format comprised: i) two murine monoclonal antibodies targeting HCV core amino acid (aa) 
residues 21-40 and 70-90 were used for capturing HCV core Ag, ii) a rabbit polyclonal anti-
HCV core antibody targeting aa 9-21 as primary detector antibody, and iii) anti-rabbit IgG 
conjugated with horseradish peroxidase (HRP) as secondary detector antibody. TMB was 
used as enzyme substrate. 
Table 2.1 Reagents used for the HCV core antigen EIA development 
Capture Antibodies 
 
Murine monoclonal antibodies to HCV core antigen; target 
epitopes: aa21-40 (Thermo Scientific). This is a21kDal 
protein well conserved among different HCV genotypes 
Clone: C7-50 (Bukh et al, 1994). 
Detector Primary Antibody Rabbit polyclonal antibodies to HCV core antigen; target 
epitopes: aa 9-21 (Antibodiesonline.com). 
Detection Conjugate Stabilised Goat anti-rabbit IgG  (Heavy and Light Chain) 
Antibody- HRP (Thermo Scientific) 
Positive Control Hepatitis C core antigen protein; recombinant fragment 
corresponding to amino acids 2-119 of hepatitis C. 
Substrate 1 step Ultra TMB – ELISA (Thermo Scientific) 
Washing Buffer PBS /0.05%  Tween 20 
Stop Solution 1N  H2SO4 
Blocking Buffer BSA/PBS 
ELISA Plate  96-well flat bottom ELISA plates (Thermo Scientific) 
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2.5.2  Antibodies Selection 
Antibodies were selected based on:  
1. Antibodies used in the HCV core Ag EIA by Kawai et al and Aoyagi et al. 
2. HCV core amino acid sequences well conserved among known HCV genotypes. 
3. Commercial availability of antibodies. 
Kawai et al used antibodies that recognised HCV core aa 21-40 for capture and 41-60 for 
detection, whereas Aoyagi et al. Used antibodies targeting HCV core aa 100-120 and 120-
140 for capture and 21-40 and 41 to 50 for detection. Among these antibodies, the 
monoclonal antibody targeting aa 21-40 was found to be commercially available. Conserved 
HCV core aa sequences for all HCV genotypes were obtained from the Los Alamos HCV 
Sequence Database (Table 2.2). 
 
 
Table 2.2 Conserved HCV core amino acid sequences for all HCV genotypes on Los Alamos 
 
Epitope Sequence 
9-21 R- TKRNT-RRP DV 
 
21-48 DVKFPGGGQIVGGVY LPRR-GPRLGVRA 
50-67 RKTSERSQPRGRRQPIPK 
80-90 RKTSERSQPRGRRQPIPK 
92-105 GWAGWLLSPRGSRP 
115-129 RSRNLGKVIDTLTCG 
165-181 ATGNL-PGCSFSIFLLAL 
 
Within the 21 to 48 conserved region, the monoclonal antibody targeting aa 21-40 was 
available commercially. However, an amino acid substitution was identified at position 36 in 
published HCV genotypes 3 sequences. The leucine to valine substitution could have 
potentially led to diagnostic escape for HCV genotype 3 (Saeed et al, 2009) if only anti- 
HCV core antibody aa 21-40 was used for capture. Therefore I first identified conserved 
HCV core aa sequences for HCV genotype 3. These were: 
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1. aa 77-99  (WAQPGYPWPLYGNEGCGWAGWLL);   
2. aa111-140 (NDPRRRSRNLGKVIDTLTCGFADLMGYIPL).  
Among these, the closest antibody found commercially was a monoclonal antibody targeting 
HCV core aa 70- 90.  
 
Figure 2.2 Diagrammatic representation of the indirect sandwich ELISA format used for the 
HCV core antigen detection 
 
 
2.5.3 Microplate Coating 
1. Capture antibodies were removed from freezer/fridge and allowed to thaw to room 
temperature. Equimolar concentration of the two capture antibodies (monoclonal 
HCV core antibodies aa21-40 and aa70-90) was prepared by diluting the same volume 
of each capture antibody in PBS (pH=7.4) to the desired concentration (refer to table 
2.7). 
2. 100 µl of the mixture was pipette into the microplate wells and covered with adhesive 
plate sealer and the plate was incubated overnight (18 hours) at 4˚C  
3. The plate was then washed with PBS/0.05% Tween in 6 cycles. 
4. The wells were blocked for 2hrs at room temperature with 250 µl of  1% BSA/PBS.   
5. The blocking buffer was then discarded and the plate was blotted on tissue to remove 
excess blocking buffer. 
 
 
  Anti-rabbit IgG- HRP conjugate              
 
 
Rabbit Polyclonal antibody aa 9-21 
 
 
 
Murine monoclonal antibody aa21-40 
and aa70-90 
36 
 
2.5.4 ELISA Optimisation 
Table 2.3 shows concentrations of the various capture and detection antibodies that were used 
during the assay optimisation. A checkerboard system was used to as a guide for optimisation 
of reagents used (Table 2.4).  
Table 2.3 Reagent concentrations used for the HCV optimisation 
Reagent Concentration 
Both capture antibodies 1 µg/ml, 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml,10µg/ml 
 
Prepared from 1mg/ml stock 
Second primary antibody  1:250, 1:500, 1:1000, 1:1500  
 
Prepared from 1mg/ml of stock 
Anti-rabbit IgG-HRP conjugate 1:60, 1:120, 1:250, 1: 500, 1:1000, 1:2000, 1:5000, 1:10000    
 
Prepared from 1mg/ml stock 
Positive control 0.2µg/ml  
 
Prepared from 1mg/ml stock 
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Table 2.4 Checker board used for HCV core antigen EIA optimisation. The yellow and blue 
shaded areas indicated two different concentrations of anti-rabbit HRP conjugate. 
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Verification of Antigen-Antibody interaction 
An experiment was performed to verify whether various antigens are recognising their 
targets.  This involved:  
1. Antigen-capture antibody interaction: Microplate was coated with HCV core protein 
(positive control) and incubated with each of the capture antibodies and then both. 
The complex was then detected with anti-mouse IgG-HRP conjugate. 
2. Antigen-second primary antibody interaction: Microplate was coated with HCV core 
protein (positive control) and incubated with the second antibody (aa 9-21) and the 
complex was detected with anti-rabbit HRP. 
First and second primary antibody interaction: Microplate was coated with second primary 
antibody (rabbit polyclonal antibody aa 9-21) and then incubated with first primary 
antibodies. Detection was performed with anti-mouse IgG-HRP 
Sample Preparation – Antigen Retrieval (Kawai et al, 2002) 
Reagents used: 
a. 24% polyethylene glycol 4000 
b. 20mM sodium citrate in 5% NaCl. 
c. 10M Urea in 0.5M NaOH 
d. 0.5M NaH2PO4 in 5% Triton-X 100 
Procedure: 
1. To 200 µl of serum 40µl of 24% polyethylene glycol 4000 in was added in a 1.5mL 
Eppendorf tube. 
2. The mixture was then incubated for 1 hour at 4oC. 
3. Centrifugation at 4000g for 15 minutes. 
4. The supernatant was decanted and the precipitate formed at the bottom of the tube 
was dissolved with 25 µl of 20mM sodium citrate in 0.5% NaCl. 
5. 50 µl of 10 M urea in 0.5 M NaOH was added to the solution and incubated at 37 oC 
for 30 min. 
6. 50 µl of 0.5 M NaH2PO4 in 5% Triton X-100 was then added to the sample. 
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CHAPTER THREE – RESULTS 
3.1 ART IN THE KUMASI HIV INFECTED COHORT  
Within the study period, 1780 HIV-positive patients attending KATH for routine care were 
screened for HBsAg by the Determine and Murex assays, of which 254 were HBV infected. 
Overall 247 patients representing 97.2% of identified HIV/HBV co-infected subjects were 
recruited in the HEPIK study. Their characteristics are summarised in (Table 3.1). 
Table 3.1 Characteristics of the HIV/HBV co-infected cohort at study entry 
 
a
includes 2NRTIs+NFV and 1NRTI+NFV+LPV/r IQR = interquartile 
range; ART = antiretroviral therapy; NRTIs = nucleos(t)ide reverse 
transcriptase inhibitors; EFV = efavirenz; NVP = nevirapine; LPV/r = 
ritonavir-boosted lopinavir; NFV = nelfinavir. 
 
At the time of recruitment, 202 patients (133 females and 69 males) were ART-experienced, 
having received a median of four (range: 3-8) antiretroviral drugs for a median of 67 weeks 
(IQR: 42-147 weeks). All the 202 patients were NRTI-experienced, 201 (99.5%) were 
Characteristic Result  
Total number 247 
Age, median years (IQR)  40 (34-46)  
Gender, female n (%) 165 (66.8) 
Duration of HIV diagnosis, median years (IQR) 3  (1-5) 
CD4 count, median cells/µL (IQR) 478 (298-659) 
ART status, experienced n (%) 202 (81.8) 
Number of drugs received, median (IQR) 4 (3-4) 
Duration of ART, median years (IQR) 1 (1-3) 
ART at study entry (among ART-experienced patients), n (%) 
2NRTIs + EFV 116 (57.4)  
2 NRTIs + NVP 74 (36.6) 
2 NRTIs + LPV/r 5 (2.5) 
Other
a
 5 (2.5) 
Undergoing ART interruption 2 (1.0) 
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NNRTI-experienced and 10 (5%) were PI-experienced. Howeever two patients were 
undergoing ART interruption at study entry. The ARVs received at study entry are 
summarised in Table 3.2. 
Table 3.2 Antiretroviral drugs received at study entry among 200 patients  
 
 
 
 
 
 
 
 
 
 
 
 
At study entry the majority of patients were receiving the standard first-line ART regimen in 
use at KATH, consisting of two NRTIs plus one NNRTI. Only a small number of patients 
were receiving PI-based ART. The most common ART regimen at study entry was ZDV, 
3TC plus either EFV or NVP. Several patients were receiving d4T although this is no longer 
part of national treatment guidelines.   
 
3.2 TREATMENT CHANGES PRIOR TO STUDY ENTRY 
Prior to study entry, 102/202 (50.5%) of ART-experienced patients had undergone changes in 
the composition of the ART regimen at least once (range: 1-3). The most common involved 
NRTI to NRTI substitutions (n=93; 91.2%) including d4T to ZDV (n=73; 78.5%), ZDV to 
d4T (n=12; 12.9%) and ZDV to TDF (n=7, 7.5%); 16 patients underwent NNRTI to NNRTI 
substitutions including NVP to EFV (n=11; 64.7%) or EFV to NVP (n=7; 41.2%). The 
reasons for these changes were not systematically recorded, and are believed to reflect 
toxicity, variable drug supply and pregnancy. Only nine patients had changed from an 
Class Drug n % 
NRTI 
 
 
 
 
 
 
NNRTI 
 
 
 
 
 
PI 
3TC 194 97 
ZDV 148 74 
d4T 33 17 
 
TDF 12 6 
 
ABC 6 3 
 
DDI 
 
5 3 
 
NVP 74 37 
EFV 116 58 
 
NFV 5 3 
LPV/r 5 3 
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NNRTI- to a PI-based regimen as a result of treatment failure, defined as either a clinical 
event or a poor CD4 T-cell count response to ART. 
3.3  VIROLOGICAL RESPONSES TO ART 
In the overall 247 HIV/HBV co-infected cohort,  plasma HIV-1 RNA levels were obtained at 
study entry in 227 (91.2%) patients, of which 183 (80.6%) were ART-experienced and 44 
(19.4%) were ART naive. Among the 183 treated patients, plasma HIV-1 RNA levels were 
undetectable (<40 copies/mL) in 111 (60.6%) whereas 72 (39.3%) had detectable HIV-1 
RNA with a median load of 1061 copies/mL (IQR: 68-21476 copies/mL). 
3.3.1 Virological Responses in the Population on ART for at Least 24 Weeks 
As treatment guidelines recommend that plasma viral load should be undetectable within 6 
months of starting ART, virological responses were analysed among 155 patients who had 
been on ART for at least 24 weeks at study entry. Overall, 58 (37.4%) patients showed a viral 
load >40 copies/mL (Table 3.3). The median level was 826 copies/mL (IQR: 65 – 26752). 
CD4 T-cell counts were lower in patients with viral load >40 copies/mL compared with 
patients showing a viral load <40 copies/mL (P= 0.002, Mann Whitney U test). Overall the 
proportions with viral load <40 copies/mL were 59 (39.8%) and 38 (66.7%) among women 
and men respectively, and 56 (65.1%), 36 (60%) and 5 (55.6%) among patients receiving 
EFV, NVP and a PI respectively. The viral load levels observed in the 58 patients with >40 
copies/mL are shown in Figure 3.4.  
Of 189 patients on NNRTI-based regimens at study entry, 146 had received ART for at least 
24 weeks prior to study entry. Plasma HIV-1 RNA levels were <40 copies/mL in 92 (63%) 
patients and >40 copies/mL in 54 (37%). Among the 10 patients who were on PI-based 
regimens, five had HIV-1 RNA >40 copies/mL whereas five had a viral load <40 copies/mL 
respectively. The proportions of patients who showed virological failure are as shown in 
figure 3.1 
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Table 3.3 Characteristics of patients who had received ART for at least 24 weeks with HIV-1 
RNA levels above or below 40 copes/mL 
 HIV-1 RNA copies/mL 
 <40 >40 
Number (%) 97 (62.6) 58 (37.4) 
Age, median years (IQR) 41 (36-48) 40 (37-47) 
Gender, female n (%) 59 (60.8) 39 (39.8) 
Duration of HIV diagnosis, median years (IQR) 4 (3-6) 3 (2-5) 
CD4 count, median cells/µL (IQR) 528 (398-727) 421 (230-637) 
Number of ARVs received, median (IQR) 4 (3-4) 4 (3-4) 
Duration of ART, median years (IQR) 4 (3-5) 3 (2-5) 
ARVs at study entry, n (%)   
EFV 56 (57.7) 30 (51.7) 
NVP 36 (37.1) 24 (41.4) 
PI 5 (5.2) 4 (6.9) 
One ARV change prior to study entry, n (%) 33 (34.2) 28 (48.3) 
More than one ARV change prior to study entry, n (%) 16 (16.5) 3 (5.2) 
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Figure 3.1 Percentage of patients (n=58) meeting different thresholds for defining virological 
failure after at least 24 weeks of ART. 
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3.4 Anti-HCV Serology Results 
A total of 34, 24, 78 and 71 serum samples of known HCV RNA status were tested for the 
presence of anti-HCV antibody by two automated assays – the Architect and the Vitros, and 
two manual EIAs, the Ortho and Monolisa. Testing was based upon sample availability. Four 
HCV RNA positive samples were tested by three assays; the Vitros assay included only two 
of the four HCV-RNA positive samples (Table 3.7). Twenty-three samples were tested by all 
the four assays. The HCV-RNA positive samples were reactive by all assays. In addition, 
three HCV-RNA negative samples were reactive by Architect. These three samples were also 
reactive by the other tests, yielding a total of seven samples that were scored as “True 
positive”. 
Table 3.4 Anti- HCV detection by four serology assays 
 Tested  Assay results 
HCV RNA
+
  
n (%) 
HCV RNA
-
  
n (%) 
Total 
n 
 
 Reactive 
n (%) 
Non-reactive 
n (%) 
Equivocal 
n (%) 
ARCHITECT 4 (12) 30 (88) 34  7 (21) 27 (79) 0 
VITROS 2 (8) 22 (92) 24  8 (33) 15 (63) 1 (4) 
ORTHO 4 (5) 74 (95) 78  9 (12) 69 (89) 0 
MONOLISA 4 (6) 67 (94) 71  21 (30) 47 (66.2) 3 (4) 
 
The mean (range) signal/cut-off ratios (S/CO) obtained with reactive, non-reactive and 
equivocal sample by each assay are shown in table 3.5 
Table 3.5 Mean signal/cut-off ratios obtained with each anti-HCV assay 
 Mean S/CO (range) 
Positive Negative  Equivocal 
Archictect 8.80 (1.01-12.75) 0.16 (0.07-0.43) None 
Vitros 12.62 (1.65- 29.60) 0.49 (0.19- 0.84) 0.91* 
Monolisa 3.77 (1.21-6.62) 0.45 (0.22- 0.84) 1.02 (0.94-1.09) 
Ortho 3.97 (1.05-5.29) 0.12 (-0.01-0.68) none 
* One sample 
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3.4.1 Assay Performance 
The sensitivity, specificities, NPVs and PPVs were calculated using the number of true 
positive and negative samples as defined in chapter 2 (page 30). The performance of each 
assay based on the results for the HCV-RNA tested samples which were tested by the assay 
and Architect was analysed. A further analysis based on the 23 samples that were tested by 
all four assays was done. In a resource-limited setting a more specific rather than sensitive 
screening assays which have the potential to minimise the number of samples that require 
confirmatory test will be the cost-effective assay. Therefore in order to restrict the 
specificities of the assays the equivocal results with Vitros and Monolisa were classed with 
the reactive results.  
Table 3.6 Assay performance with respective number of tested samples  
Assay 
(n)* 
True 
+ve 
False 
+ve 
True 
-ve 
False 
-ve 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
NPV 
(95%CI) 
PPV 
(95% CI) 
Monolisa 
(31) 
7 16 8 0 100 
(59.0-100) 
33.3 
(15.6-55.3) 
100 
(62.8-100) 
30.4 % 
(13.2 -52.9) 
Ortho 
(31) 
6 1 23 1 85.7 
(42.1-99.6) 
95.8 
(78.9-99.9) 
95.8 
(78.9-99.9) 
85.7 
(42.1-99.6) 
Vitros 
(23) 
5 3 16 0 100 
(47.8-100) 
84.2 
(60.4-96.6) 
100 
(79.4-100) 
62.5 
(24.5-91.5) 
*
Indicates the number tested by the EIA and Architect plus HCV PCR. 
The Vitros assay showed a sensitivity of 100% whereas the sensitivity for the manual assays 
Monolisa and Ortho were 100% and 85.7% respectively. This reflected the fact that Ortho 
showed no reactivity with a HCV- RNA sample that gave reactivity by the Architect and two 
other assays. Specificity was highest with Ortho (95.8%), followed by Vitros (84.2%), and 
was lowest by Monolisa (33.3%). An analysis of the assay performance based on 23 samples 
tested by all four assays showed a slight reduction in sensitivity and PPV with Ortho whereas 
sensitivity with Monolisa and Vitros remained at 100%. Specificities and NPVs of Monolisa, 
Ortho and Vitros were marginally reduced as indicated in table 3.7.    
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Table 3.7 Assay performance with same samples tested by all four assays. 
Assay 
(n) 
True 
+ve 
False 
+ve 
True 
-ve 
False 
-ve 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
NPV 
(95%CI) 
PPV 
(95% CI) 
Monolisa 
 
5 14 4 0 100 
(48.7-100) 
22.2 
(6.4-47.6) 
100 
(39.8-100) 
26.3 
(9.2-51.2) 
Ortho 
 
4 1 17 1 80.0 
(28.4-99.5) 
94.4 
(72.7-99.9) 
94.4 
(72.7-99.9) 
80.0 
(36.0-98.0) 
Vitros 
 
5 3 15 0 100 
(47.8-100) 
83.3 
(58.8-96.4) 
100 
(78.2-100) 
62.5 
(24.5-91.5) 
 
The lowest (S/CO) that corresponded to a true positive result was 1.65 with Vitros, 1.52 with 
Monolisa and 1.15 with Ortho. The S/CO ratio obtained with true positive samples by 
Monolisa was significantly higher than that obtained with false positive results. The mean 
S/CO obtained with true positives, false positives, and true negatives are as shown in table 
3.8 
Table 3.8: Mean (range) signal/cut-off ratios according to the definition of true and false 
positive and negative. 
 Mean S/CO (range)  
   
 True positives False positive True negatives False negative 
Vitros 15.2 (1.65-29.60) 4.38 (0.91-10.43) 0.49 (0.19-0.84) ― 
Monolisa 5.06 (1.52-6.45) 2.2 (0.94-5.99) 4.35 (1.15-5.29) 0.29* 
Ortho 4.35 (1.15-5.29) 1.49* 0.17 (-01-0.7) ― 
* One sample 
 
The mean S/CO ratios obtained with true positive results was higher than that obtained with 
false positive results by Monolisa (P=0.0006, t test). However, 10/16 (65%) of false positive 
samples showed an S/CO ratio within the range obtained with true positive S/CO ratios. 
Similar observations were made with Ortho, as the S/CO of the only false positive sample 
was within the range of values obtained with true positive samples. Also, there was no 
significant difference between the mean S/CO ratios obtained with true positive and false 
positive results by Vitros. 
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3.4.2 Comparison between Monolisa and Ortho 
Given the lack of automated platforms in Kumasi, we had interest in evaluating manual EIAs 
for their performance. Therefore the performance of Monolisa and Ortho was assessed. Of 
the 71 and 78 samples tested by Monolisa and Ortho respectively, the rate of HCV 
seropositivity was 29.6% (24/71) by Monolisa and 11.5% (9/78) by Ortho. The median S/CO 
ratio for seropositive samples was 3.05 (range, 1.21-6.62) for Monolisa and 4.89 (range, 1.05-
5.29). The median S/CO ratio with antibody negative results were 0.38 (range, 0.22-0.84) for 
Monolisa and 0.05 (range, -0.01-0.68). Three samples were identified by Monolisa as 
equivocal with average S/CO of 1.02 whereas there was no equivocal result by Ortho.  
Monolisa was found to be more sensitive for HCV antibody detection in the Kumasi HIV 
cohort compared to Ortho (100% vs. 85.7%) whereas specificity of Ortho was higher than 
Monolisa (95.8% vs. 33.3%). There was a higher rate of false positivity by Monolisa 
compared to Ortho (51.6% vs. 2.8%) resulting in a lower specificity by Monolisa than Ortho 
(33.3% vs. 95.8%). Monolisa was found to have a negative predictive value higher than 
Ortho (100% vs. 95.8%) but had a lower positive predictive value compared to Ortho (30.4% 
vs. 85.7%). The median S/CO ratio of the true HCV seropositive samples was 5.92 (range: 
1.52-6.45) for Monolisa and 4.97 (range: 1.15-5.29) for Ortho. These results indicated that 
the Ortho assay is better suited for use in Kumasi, as it would result in fewer samples 
requiring unnecessary additional investigations due to false positivity. 
3.4.3 Assay performance in relation to HCV RNA results 
The results of the HCV molecular epidemiological studies performed by Simon King in the 
Kumasi cohort showed a HCV RNA prevalence of 0.64% (8/1249). Four of the positive 
samples were available for antibody testing by the Architect, Monolisa and Ortho and two 
had sufficient volume to also allow testing by Vitros. 
The mean S/CO ratios with for HCV RNA detection by the four assays were as shown in 
table 3.9. 
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Table 3.9: Mean (range) signal/cut-off ratios according to HCV RNA detection  
 Mean S/CO ratio (range) 
HCV RNA Positive HCV RNA Negatives 
Architect 11.03 (7.24-12.75) 0.5 (0.07-5.15) 
Vitros 26.65(23.70-29.60) 2.36 (0.19-19.3) 
Monolisa  6.28 (5.92-6.45) 1.02 (0.22-5.99) 
Ortho 5.10 (4.87-5.29) 0.26 (-0.01-4.53) 
 
Possible assay cut-offs that are likely assay to be indicative of  HCV RNA positivity were 
obtained by using the lower S/CO value  obtained by each assay with HCV RNA positive 
samples, minus 25%. The values obtained were Architect, 5.43, Vitros, 17.77, Monolisa, 
4.44, and Ortho, 3.65. The results with Vitros may have been different if all the RNA positive 
samples were tested.  
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3.5 HEPATITIS C CORE ANTIGEN ELISA DEVELOPMENT 
3.5.1  ELISA Optimisation 
Repeated experiments using reagents at the various concentrations as indicated in Table 2.7 
of methodology, blanks, control and sample wells were reactive with a low signal to noise 
ratio (<1) even at the lowest concentrations of all the capture and detection reagents 
indicated. In an attempt to minimise the background reactivity, the experiment was repeated 
with increased blocking of the antibody-coated wells. This was done by experimenting with 
1. detection primary antibody (rabbit polyclonal aa 9-21) and the anti-rabbit IgG-
HRP conjugate diluted in 0.05% Tween 20 in 1% BSA/PBS, 
2. blocking coated plate overnight with 1% BSA/PBS at 4˚C 
3. increasing the conjugate titrating range from  1:60 – 1: 250 to 1:1000 to 1:10 000 
No signal was obtained in all of the above experiments. 
 
Figure 3.2 Optical density comparisons for blanks, controls and samples during ELISA 
optimisation.
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3.5.2 Verification of Antigen-Antibody Interaction 
A verification of the reactivity of the various antigens or antibodies with their respective 
targets was then performed as outlined in Methods. Results are summarised in Table 3.11. 
Table 4.0 Interaction of HCV core proteins with the various anti-HCV core antibodies 
employed in the ELISA development 
Interaction Results 
HCV Core  protein (0.2µg/mL) and capture antibodies 
1.       aa21-40 and 
2.       aa70-90 
3. Equimolar concentration of both 
 
All reactive with high 
background 
HCV core protein and detection primary antibody (aa 9-21) Non reactive 
Anti- HCV core antibodies (aa21-40 and aa70-90) and 
detection primary antibody (aa 9-21) 
Non reactive 
 
The HCV core ELISA development was discontinued at this point and the indirect sandwich 
format regarded as unsuitable for further development with commercially available reagents. 
Further steps that could have been undertaken include. 
1. Test an alternative commercial source of antibodies 
2. Identification of antibodies targeting a different aa residue  
3. Optimise concentrations of capture and detection antibodies to obtain the minimal 
concentrations at which positive and controls are appropriately identified with and the 
minimal background noise. 
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CHAPTER FOUR – DISCUSSION 
Molecular testing plays a critical role in the management of HIV-infected patients, including 
confirming diagnosis, assessing prognosis and disease progression, guiding initiation of ART 
and treatment selection, monitoring therapeutic success and detection failure and drug 
resistance. However, access to molecular testing is limited in Kumasi and the rest of Ghana. 
Thus, there has been lack of routine virological monitoring in the management of HIV 
patients since the inception of ART at the KATH HIV clinic in Kumasi. This is mainly due to 
the lack of laboratory infrastructure and expertise for molecular testing. One aim of this 
research work was to develop proficiency in the area of HIV and HCV molecular testing. 
This was achieved over three months through observation and practice, followed by 
successful testing of a blinded proficiency panel. The techniques applied, included both 
manual and automated nucleic acid extraction, assay specific pre-PCR master mix 
preparation, quantitative real-time PCR, and results interpretation. These skills acquired will 
be applied to provide molecular testing to help improve the management of HIV in Kumasi 
once the necessary infrastructures are put in place, namely purchasing a real-time PCR 
machine and identifying suitable laboratory space to allow a gold-standard PCR work flow to 
be set in place. The knowledge acquired will also be shared with laboratory and non-
laboratory colleagues at work, with the objective of building capacity for molecular testing in 
infectious diseases.  
With the limited resources for routine viral load testing in Kumasi and other treatment centres 
in Ghana, clinicians depend on clinical evaluation and CD4 T-cell counts to monitor 
responses to ART and decide when to change to an alternative regimen. However, this 
approach has been proven to be less sensitive for determining treatment failure (Rawizza et 
al, 2011, Boullé et al, 2013). Using CD4 T-cell counts in particular may lead to treatment 
being inappropriately changed in some patients, whereas others may experience prolonged 
virological failure before treatment is changed, leading to the accumulation of drug resistance 
and other negative consequences of uncontrolled HIV replication. Waiting for the CD4 T-cell 
count to drop or for a clinical event to occur may increase the risk of mortality in those 
patients. Moreover, uncontrolled viral replication under drug pressure may have negative 
public health implications, including persistence risk of HIV transmission, including the 
transmission of resistant strains. The latter is likely to compromise first-line ART regimens 
given the absence of resistance testing prior to starting ART in Ghana.  
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This study found that among HIV-infected patients receiving ART at KATH, whereas the 
majority had undetectable plasma HIV-1 RNA after at least 24 weeks of ART, 37% had a 
detectable viral load (< 40 copies/mL).  Of these, 36.2% showed virological failure based on 
the WHO definition (WHO, 2010). Multiple factors may have resulted in this outcome, 
including suboptimal adherence, use of less favourable ART regimens, and baseline clinical, 
immunological and virological determinants (Kwobah et al, 2012; Harrigan et al, 2005; 
Datay, 2010). We also detected a high number of intra-class drug changes in this population, 
which resulted from problems of toxicity or drug supply, which in turn may have affected 
adherence. Furthermore, the impact of transmitted and acquired HIV drug resistance has not 
been evaluated in this population. Recent surveys have shown that in resource-poor settings 
ART-induced resistance is about 7.2 % 6-11 months of therapy, increasing to 21% in patents 
on ART for 36 months or longer.(Fig 4.1) (Stadeli et al, 2013). In parallel, rates of 
transmitted drug resistance have also increased, and are about 5.7 % in Africa (Stadeli et al, 
2013). 
Figure 4.1. Prevalence of treatment-associated HIV drug resistance in Africa, Asia, and 
Brazil in studies published before November 2011(adapted from Stadeli et al, 2013) 
 
 
 
 
 
 
 
 
 
A cross-sectional study conducted among women participating in a HIV prevention trial in 
South Africa showed that 7.4% of those newly identified as HIV positive at screening already 
had HIV drug resistance, especially to the NNRTIs (Parikh et al, 2013). 
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Figure 4.2 MTN-009: HIV drug resistance in women screened for HIV prevention trials. The 
frequency of specific resistance-associated mutations (RAMs) for the three main ART classes 
is shown. 
 
 
 
 
 
 
 
 
 
 
This observation underscores the need for access to regular viral load and resistance testing 
both at baseline and during ART in Kumasi. Currently CD4+ T-cell count testing is 
performed every 3 months during follow up at the KATH HIV clinic. If the right facilities are 
installed viral load testing could be done every 6-12 months to replace CD4 count for patients 
on ART. This will enable clinicians to detect early virological failure and initiate a timely 
change in regimen before extensive drug resistance accumulates, and the risk of HIV 
transmission and clinical and immunological deterioration increase. However to make the 
results more useful to patients’ management, it will be necessary to have a wider range of 
alternative regimen at the centre for patients who fail with the initial drugs. An additional 
consideration will be the cost effectiveness of implementing viral load testing as an ART 
monitoring strategy. Although early diagnosis, CD4 count testing and clinical monitoring 
increase the potential life expectancy of people infected with HIV (Nagakawa et al, 2011; 
Phillips et al, 2008; Bendavid et al, 2008), modelling studies for resource-limited settings 
have shown relatively higher incremental life expectancy with viral load monitoring (Phillips 
et al, 2008; Bendavid et al, 2008). However higher lifetime cost of running viral load 
produces a higher incremental cost effectiveness ratio (the ratio of the change in costs to 
incremental benefits of an intervention or treatment) compared to CD4 count and clinical 
monitoring which will be economically less favourable in the dominant low-income settings 
in SSA including Ghana. In a South African model, an addition of viral load testing to CD4 
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count monitoring at every 6 months cost $5414 per life-year gained (Bendavid et al, 2008). 
Furthermore, the cost effectiveness of viral load is markedly influenced by the cost of 
second-line treatment (Kimmel et al, 2010). In the South African model CD4 count testing 
showed life improved life years two months lower than virological monitoring. This indicates 
that CD4 count monitoring still shows as a good strategy for improving life expectancy. 
However, the use of CD4 count and clinical monitoring without virological monitoring will 
eventually lead to a higher risk of HIV transmission and onward transmission of resistant 
strains. There is therefore the need to explore cheaper viral load monitoring techniques in 
Ghana that will help mitigate the impact of the lack of virological monitoring on public 
health. Point of care viral load testing could be the cost-effective strategy to explore in 
resource-limited settings (Estill et al, 2013). Some viral load techniques that can be explored 
include the Exavir Load assay from Cavidi (Sweden). This technique has been shown by a 
study in Botswana to be five times cheaper compared to the standard techniques currently 
available and has limit of detection of 1000 copies/mL (Cairns, 2009). In anticipation of the 
infrastructure for viral load testing in Ghana, it is important to keep the widening of access to 
ART as a priority. 
The results of this work provide the basis for further characterisation of the ART response 
among treated patients in Kumasi. A follow-up to this work will focus on measuring 
virological responses longitudinally and detecting HIV drug resistance among patients with 
detectable HIV-1 RNA to assess the rate of emergence of drug resistance by treatment 
duration.  We hope that some of these tests will be conducted in Kumasi where samples and 
clinical data are still being collected. Furthermore, we wish to perform a formal statistical 
analysis of factors associated with detectable viral load by logistic regression. Finally, given 
that our population was HBV co-infected, we wish to explore whether rates of virological 
failure are similar in HBV-positive and HBV-negative patients.  
Documented HBV prevalence ranges from 6% to 16% in the general population in Ghana 
(Acquaye, 1991; Acquaye and Mingle, 1994; Martinson et al, 1996) whereas a prevalence of 
16.8% has been found in HIV co-infected patients in Kumasi (Geretti et al, 2010). Despite 
this high rate of HBV co-infection, screening for viral hepatitis in HIV patients is performed 
only in selected cases to exclude liver toxicity due to ART. As more HIV patients survive 
with increased access to ART, chronic liver disease in co-infected patients will emerge as a 
threat and therefore characterisation of viral hepatitis among co-infected patients will be of 
grave importance. A previous research by Geretti et al, 2010 is performing detailed HBV 
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prevalence studies in the Kumasi HIV cohort and monitoring liver disease in this population 
using laboratory tests and fibroscanning.  
Among the currently available antiretroviral drugs in Ghana, those that are known to be 
active against both HIV and HBV are FTC, 3TC and TDF (Dore et al, 2010). 40% of HBV 
infected patients receiving 3TC monotherapy risk HBV resistance after 2 years of therapy 
and the risk is higher with HIV co-infection and duration of therapy (Benhamou et al, 1999; 
Cooley et al, 2003). FTC also demonstrates similar efficacy and resistant pattern to 3TC. 
TDF is currently the preferred ARV drug having dual activity against HBV and HIV and has 
an additional potency against 3TC/FTC resistant HBV (WHO, 2011). An interesting result 
from this study however indicates that minority (6%) of the HIV/HBV cohort from Kumasi 
were treated with TDF whereas the majority (97%) were treated with 3TC. This indicates a 
high risk of drug resistance as a result of poor treatment of HBV infection in coinfected HIV 
patients. 3TC induced mutations in HBV polymerase, the target of therapy, could also lead to 
mutations in the HBsAg, the target of vaccine-induced protective antibodies and diagnostic 
assays , due to the overlap of the polymerase and surface open reading frames, leading to loss 
of recognition by either or both (Sheldon et al, 2008; Torresi et al, 2002). The screening for 
HBV in HIV patients prior to treatment and including TDF in the regimen for the treatment 
of co-infected patients in Kumasi will be important to avert HBV related diseases and the 
spread of HBV mutant strains which could impact negatively on public health. 
On the other hand, data on the prevalence of HCV infection in both the general population 
and HIV-positive patients in Ghana are limited. Seroprevalence rates ranging from 0.5% to 
18.7% have been documented in different Ghanaian populations (Acquaye et al, 2000; 
Owusu-Ofori et al, 2005; Nkrumah et al, 2011). Two studies showed 3.6% and 17% 
seroprevalence among HIV patients (Sagoe et al, 2012; Apea-Kubi et al, 2006). 
A problem with the uneven results from the various HCV seroprevalence studies is the 
difference in the specificities and sensitivities of the assays employed and the fact that none 
of them attempted HCV RNA detection by PCR or confirmation of seropositivity by RIBA.  
In this study, samples with known HCV RNA status were screened with four commercial 
serological assays, namely the Architect, the Vitros, the Monolisa and the Ortho. The HCV 
PCR was performed using serum and DPS. The DPS provided the benefit of cheap and easy 
means of sample transportation, and worked well indicating that centralised testing in a 
laboratory with molecular testing facilities may be feasible. 
56 
 
The accurate detection and treatment of hepatitis C in a limited resource setting requires the 
use of a sensitive but more importantly, specific serological assays which have the highest 
probability to capture HCV RNA positive samples. This is in order to reduce the number of 
samples that require HCV RNA confirmation. Architect is a well-established automated assay 
that has been proven to have high specificity and sensitivity (99.8% and 100% respectively) 
in the UK; however this automated system is currently not available in Ghana. The 
performance of two manual EIAs that could be implemented in Kumasi, the Monolisa and the 
Ortho, was therefore evaluated. Ortho was found to be less sensitive but more specific than 
Monolisa and would be the preferred choice to be used in Kumasi. To be able to use the 
Ortho as a reliable assay to differentiate between HCV RNA positive and negative samples, 
the cut-off for positivity could be set at around 3.65, which is 25% lower than the smallest 
S/CO ratio associated with HCV RNA positivity in this study. However this cut-off should be 
interpreted with caution and further studies are required to confirm this cut-off since a limited 
number of HCV RNA positive samples were available. In this context it is worth noting that 
results from Simon King’s molecular epidemiological studies indicate a low HCV prevalence 
of 0.64% in the Kumasi HIV cohort. This indicates that documented seroprevalence in Ghana 
must be interpreted with caution. 
The Monolisa assay showed a lower specificity than reported in UK evaluations (HPA-
MiDAS, 2006) and the manufacturer’s insert. The reason for this poor specificity is unclear.  
Suboptimal specificity of some manual EIA assays has been previously observed in Africa, 
including most notably the variable performance seen with type-specific herpes simplex virus 
(HSV) serology studies (Biraro et al, 2011). In these HSV studies, increasing the assay cut-
off for positivity improved specificity, although assay performance showed geographical 
variability (Mujugira et al, 2011) 
HCV core antigen (Ag) has been shown to have a linear correlation with plasma HCV RNA 
(Ayoyagi et al, 1999, Kawai et al, 2002, Widell et al, 2002) and can be detected with a 
simple manual EIA. However there are currently no commercial assays for HCV Ag 
detection, although combine HCV antibody/antigen assays have been introduced. We 
attempted to develop a HCV Ag assay for its potential to be used as a surrogate for HCV-
RNA detection where resources for molecular testing are limited, and as a one-step screening 
test for HCV.. An indirect sandwich method was attempted, which was contrary to the direct 
sandwich principle used by two previously published in- house HCV core EIAs. The reason 
was because the former is assumed to have a higher specificity than the latter. The assay was 
troubled by high background. Standard strategies were followed to resolve the non-specific 
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binding without success. It should be noted that among the primary and secondary antibodies 
used in previously published studies only one, recognising aa21-40 of the HCV core, was 
commercially available at the time this study was started. Surprisingly, after several failed 
attempts, the primary detection antibody (recognising the HCV core amino acid residue 9-21) 
was found not to react with the HCV core protein used as positive control under the 
conditions used. Further steps that could have been taken to develop the assay were to obtain 
a new source of antibody and revert to a direct sandwich format. 
Currently treatment of hepatitis C is not widely accessible in the general population of Ghana 
and there is no nationally adopted treatment algorithm. This may be due to high cost of 
treatment but possibly due to the fact that the burden of HCV in the general population 
including HIV co-infected patients has not been systematically assessed. As more HIV/HCV 
co-infected patients survive with ART implications are that more co-infected patients will be 
at a higher risk of HCV associated liver fibrosis, cirrhosis, hepatocellular carcinoma and 
mortality. Regular screening of hepatitis C for people with HIV will be important for the 
evaluation of the need and cost-effectiveness of HCV treatment inclusion in the management 
of co-infected patients.   
 
 
Conclusions 
This study gave me the opportunity to develop molecular and serology skills, and to apply 
myself to trouble-shooting the development of an EIA assay. Research findings were that the 
majority of patients receiving ART at KATH were responding well to treatment. A 
substantial number however had plasma HIV-1 RNA detected after at least 24 weeks of 
therapy. There are important implications in terms of health status and risk of emerging HIV 
drug resistance and onward HIV transmission. Furthermore, given that the findings 
specifically involved patients co-infected with HBV, there are also potentially severe 
implications for the progression of liver disease in this subset. The issue of liver disease is 
important in HIV-infected patients, as improved survival through ART means that chronic 
hepatitis has the opportunity to progress and cause disease and mortality. Neither HBV nor 
HCV screening are routinely available among HIV-infected patients in Kumasi. HBV appears 
to be the bigger problem however as prevalence rates are significantly higher than those for 
HCV. There are no rapid tests for HCV available in Ghana and well validated tests are 
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lacking elsewhere. We found that the performance of HCV serological assays varied with the 
Kumasi samples, with some tests showing better specificity than others. Furthermore we 
suggest a cut-off that may help to identify the patients that are most likely to test HCV RNA 
positive, although further data are required. Although development of a HCV Ag test did not 
succeeded, the experimental work was highly educational because of the trouble-shooting 
that was undertaken at each step of the assay development. 
Future Work 
The planned follow up to this work will include: 
1. In the treated HIV cohort in Kumasi, we will i) ask the statisticians for help in 
conducting a formal statistical analysis to identify factors associated with a detectable 
HIV-RNA on treatment; ii) obtain follow-up samples for longitudinal evaluations; iii) 
perform HIV drug resistance testing; and iv) compare ART response between patients 
with or without HBV infection. 
2. Continue to collect DPS for future molecular tests including further HCV RNA 
testing that will increase the number of HCV RNA positive samples available, 
allowing further refinement of serology cut-off values that are predictive of HCV 
RNA positivity in this cohort.  
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